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Abstract: In der Krebsforschung herrscht heutzutage die Ansicht vor, dass das Tumorwachstum, Tumor-
rezidive sowie die Entwicklung von Chemoresistenzen auf Krebsstammzellen zurückzuführen sind. Diese
Krebsstammzellen sollen ihre Eigenschaften mit jenen adulter Stammzellen gemein haben, wie es für
die akute myeloische Leukämie gezeigt wurde. Krebsstammzellen solider Tumoren werden, wenn immer
möglich, anhand von Zelloberflächenmarkern identifiziert, welche für die adulten Stammzellen des betrof-
fenen Gewebes bekannt sind. Diese Vorgehensweise ist nicht möglich wenn Oberflächenmarker adulter
Stammzellen nicht bekannt sind. In solchen Spezi- alfällen wird eine funktionelle Methode zur Iden-
tifizierung der Krebsstammzellen namens „side population“ (SP)-Methode verwendet. Das Ziel dieser
Forschungsarbeit war ursprünglich die Identifizierung von Krebs- stammzellen des malignen Pleurame-
sothelioms (MPM) anhand dieser funktionellen Methode. Das maligne Pleuramesotheliom ist ein Tu-
mor, welcher von Mesothelzellen ausgeht, nachdem sich Asbestfasern in der Pleura, welche die Lunge
umschliesst, anreicherten. Dieser Tumor ist sehr bösartig und weisst eine mittlere Überlebensrate von
einem Jahr ab Diagnose auf. Zudem macht sein schlechtes Ansprechen auf die Chemotherapie sowie
sein zunehmendes Auftreten notwendig mehr über seine Ent- stehungsbiologie zu erfahren. Das Daten-
material dieser Forschungsarbeit zeigt die Existenz von SP-Zellen im MPM auf. Wir konnten in vitro
zeigen, dass SP-Zellen des Pleuramesothelioms Ei- genschaften zur Selbsterneuerung sowie Ausdifferen-
zierung aufweisen, wie es das Krebsstammzellen-Modell besagt. In Xenotransplantationsexperimenten
in Mäusen beobachten wir die Tendenz von SP Zellen zu grösserer Tumorentwicklung vergli- chen mit
nicht-SP (NSP)-Zellen. Tumore, welche sich von SP-Zellen entwickelten, wiesen einen erhöhten An-
teil an sarcomatoiden MPM auf. Dieser Sub-Typ ist der aggressivere der MPM Sub-Typen und ähnelt
einem Vorläuferzellen-Phänotyp. Ein erhöhter Anteil an sarcomatoiden Mesotheliomzellen wurde auch in
wiederkehrenden Tumoren von Patienten festgestellt. Zudem konnten wir zeigen, dass MPM-SP-Zellen
im Vergleich zu NSP-Zellen resistenter gegenüber Chemotherapeutika waren. Zusammenfassend haben
wir im malignen Pleuramesotheliom Zellen identifiziert, welche selbsterneuernde Eigenschaften in vitro,
die Tendenz erhöhter Tumorent- wicklung in vivo, sowie erhöhte Chemoresistenz aufweisen. Zusätzlich
beobachten wir, dass Tumore, welche von MPM-SP-Zellen hervorgehen, Merkmale aufweisen, welche auch
bei wiederkehrenden, sarcomatoiden Tumoren von MPM-Patienten be- obachtet wurden. Recently it has
been hypothesized that tumor development, recurrence and chemo- resistance are due to cancer stem
cells (CSCs). The latter may share properties of tissue stem cells, as demonstrated for acute myeloid
leukemia (AML). In solid tu- mors, where possible, CSCs are identified according to the expression of
known stem cell surface markers of the tissue of origin. Where this approach is not possible due to the
lack of known stem cell surface markers, a functional assay called side population (SP) assay is used. The
aim of this study was originally to use such an approach to identify cancer stem cells of malignant pleural
mesothelioma (MPM). Malignant pleural mesothelioma is a tumor of mesothelial origin developing after
exposure to asbestos fibers in the pleura, which surrounds the lung. Due to its severity with a survival
rate of around one year after diagnosis, the development of chemoresistance and the increasing incidence,
it is of great importance to gain more insight into the biology of MPM. The data obtained in this study
revealed the presence of SP cells in MPM. As the CSC model claims, these SP cells have self-renewal
and differentiation capacity, which was observed for MPM SP cells in vitro. In a xenograft mouse model
we ob- served the tendency of SP cells to be more tumorigenic in vivo compared to non-side population
(NSP) cells. Tumors developed from SP cells contained cells with an in- creased spindeloid morphology.
The latter is a more severe subtype of MPM and may represent a precursor phenotype. The increase
of sarcomatoid histotype was also observed in patients with recurring MPM. Additionally it could be
observed that the chemoresistance of SP cells was increased compared to NSP cells. In summary we
identified in MPM a subset of cells with self-renewal capacity in vitro, tendency of increased tumorigenic-
ity in vivo, with increased chemoresistance and which developed tumors mimicking recurrence tumors.
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1 ZUSAMMENFASSUNG 
In der Krebsforschung herrscht heutzutage die Ansicht vor, dass das Tumorwachs-
tum, Tumorrezidive sowie die Entwicklung von Chemoresistenzen auf Krebsstamm-
zellen zurückzuführen sind. Diese Krebsstammzellen sollen ihre Eigenschaften mit 
jenen adulter Stammzellen gemein haben, wie es für die akute myeloische Leukämie 
gezeigt wurde. Krebsstammzellen solider Tumoren werden, wenn immer möglich, 
anhand von Zelloberflächenmarkern identifiziert, welche für die adulten Stammzellen 
des betroffenen Gewebes bekannt sind. Diese Vorgehensweise ist nicht möglich 
wenn Oberflächenmarker adulter Stammzellen nicht bekannt sind. In solchen Spezi-
alfällen wird eine funktionelle Methode zur Identifizierung der Krebsstammzellen na-
mens „side population“ (SP)-Methode verwendet. 
Das Ziel dieser Forschungsarbeit war ursprünglich die Identifizierung von Krebs-
stammzellen des malignen Pleuramesothelioms (MPM) anhand dieser funktionellen 
Methode. Das maligne Pleuramesotheliom ist ein Tumor, welcher von Mesothelzellen 
ausgeht, nachdem sich Asbestfasern in der Pleura, welche die Lunge umschliesst, 
anreicherten. Dieser Tumor ist sehr bösartig und weisst eine mittlere Überlebensrate 
von einem Jahr ab Diagnose auf. Zudem macht sein schlechtes Ansprechen auf die 
Chemotherapie sowie sein zunehmendes Auftreten notwendig mehr über seine Ent-
stehungsbiologie zu erfahren. 
Das Datenmaterial dieser Forschungsarbeit zeigt die Existenz von SP-Zellen im 
MPM auf. Wir konnten in vitro zeigen, dass SP-Zellen des Pleuramesothelioms Ei-
genschaften zur Selbsterneuerung sowie Ausdifferenzierung aufweisen, wie es das 
Krebsstammzellen-Modell besagt. In Xenotransplantationsexperimenten in Mäusen 
beobachten wir die Tendenz von SP Zellen zu grösserer Tumorentwicklung vergli-
chen mit nicht-SP (NSP)-Zellen. Tumore, welche sich von SP-Zellen entwickelten, 
wiesen einen erhöhten Anteil an sarcomatoiden MPM auf. Dieser Sub-Typ ist der 
aggressivere der MPM Sub-Typen und ähnelt einem Vorläuferzellen-Phänotyp. Ein 
erhöhter Anteil an sarcomatoiden Mesotheliomzellen wurde auch in wiederkehrenden 
Tumoren von Patienten festgestellt. Zudem konnten wir zeigen, dass MPM-SP-Zellen 
im Vergleich zu NSP-Zellen resistenter gegenüber Chemotherapeutika waren. 
Zusammenfassend haben wir im malignen Pleuramesotheliom Zellen identifiziert, 
welche selbsterneuernde Eigenschaften in vitro, die Tendenz erhöhter Tumorent-
wicklung in vivo, sowie erhöhte Chemoresistenz aufweisen. Zusätzlich beobachten 
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wir, dass Tumore, welche von MPM-SP-Zellen hervorgehen, Merkmale aufweisen, 
welche auch bei wiederkehrenden, sarcomatoiden Tumoren von MPM-Patienten be-
obachtet wurden. 
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2 SUMMARY 
Recently it has been hypothesized that tumor development, recurrence and chemo-
resistance are due to cancer stem cells (CSCs). The latter may share properties of 
tissue stem cells, as demonstrated for acute myeloid leukemia (AML). In solid tu-
mors, where possible, CSCs are identified according to the expression of known 
stem cell surface markers of the tissue of origin. Where this approach is not possible 
due to the lack of known stem cell surface markers, a functional assay called side 
population (SP) assay is used. 
The aim of this study was originally to use such an approach to identify cancer stem 
cells of malignant pleural mesothelioma (MPM). Malignant pleural mesothelioma is a 
tumor of mesothelial origin developing after exposure to asbestos fibers in the pleura, 
which surrounds the lung. Due to its severity with a survival rate of around one year 
after diagnosis, the development of chemoresistance and the increasing incidence, it 
is of great importance to gain more insight into the biology of MPM. 
The data obtained in this study revealed the presence of SP cells in MPM. As the 
CSC model claims, these SP cells have self-renewal and differentiation capacity, 
which was observed for MPM SP cells in vitro. In a xenograft mouse model we ob-
served the tendency of SP cells to be more tumorigenic in vivo compared to non-side 
population (NSP) cells. Tumors developed from SP cells contained cells with an in-
creased spindeloid morphology. The latter is a more severe subtype of MPM and 
may represent a precursor phenotype. The increase of sarcomatoid histotype was 
also observed in patients with recurring MPM. Additionally it could be observed that 
the chemoresistance of SP cells was increased compared to NSP cells. 
In summary we identified in MPM a subset of cells with self-renewal capacity in vitro, 
tendency of increased tumorigenicity in vivo, with increased chemoresistance and 
which developed tumors mimicking recurrence tumors. 
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3 INTRODUCTION 
3.1 MALIGNANT PLEURAL MESOTHELIOMA 
Malignant pleural mesothelioma is the most common neoplasm of the mesothelium, 
which is the lining of several body cavities such as the pleura, pericardium and the 
peritoneum as well as the tunica vaginalis1 (Mutsaers and Wilkosz, 2007). Malignant 
pleural mesothelioma is associated with exposure to asbestos fibers (Wagner et al., 
1960). Exposure occurs either occupationally, para-occupationally (i.e. mine worker’s 
wives), or non-occupationally (i.e. environmentally) (Moore et al., 2008). In very rare 
cases it occurs spontaneously (Moore et al., 2008). 
It is a devastating disease with a survival rate of around 12 months after diagnosis 
(Stahel and Weder, 2009). Despite asbestos ban in the 1990s, its incidence is still 
rising with an expected peak in 2020 (Peto et al., 1999). 
3.1.1 ANATOMY OF THE PLEURA 
The pleura is a serous membrane surrounding the lung. It is subdivided into the vis-
ceral (inner) pleura directly adjoining the lung and the parietal (outer) pleura covering 
the chest wall including the diaphragm and the mediastinum (Figure 1) (Mutsaers and 
Wilkosz, 2007). The space between the visceral and parietal pleura is the pleural 
space; it is enclosed and contains pleural fluid composed of glycoprotein-rich fluid 
and has a low cell count containing rare macrophages, mesothelial cells and lympho-
cytes (Murali et al., 2010). The composition of the visceral and parietal pleura in-
cludes five layers starting from the pleural surface: the mesothelium (Figure 2, no. 1), 
a thin layer of submesothelial connective tissue (Figure 2, no. 2), a superficial elastic 
tissue layer (Figure 2, no. 3), a second loose sub-pleural connective tissue layer rich 
in arteries, veins, nerves and lymphatics (Figure 2, no. 4) and a deep fibroelastic lay-
er adherent to the underlying lung parenchyma, chest wall, diaphragm or mediasti-
num (Figure 2, no. 5) (Wang, 1998). 
 
 
 
 
 
                                            
1 Serous covering of the testis 
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3.1.2 THE MESOTHELIUM 
The mesothelium is composed of specialized mesothelial cells forming a monolayer. 
Fully differentiated mesothelial cells (25 m in diameter) are predominantly flattened, 
squamous-like cells (Mutsaers and Wilkosz, 2007) with microvilli at their luminal sur-
face, to enlarge the cell surface area of secreting/absorbing cells (Murali et al., 2010). 
Mesothelial cells show denser distribution of microvilli at the visceral pleura and a 
more sparse density at the parietal pleura (Murali et al., 2010). 
Mesothelial cells have epithelial as well as mesenchymal characteristics (LaRocca 
and Rheinwald, 1984, Herrick and Mutsaers, 2004) such as the expression of epithe-
lial marker cytokeratin, polygonal cell shape, the secretion of basement membrane 
and the expression of mesenchymal vimentin and desmin (Herrick and Mutsaers, 
2004). Upon tissue injury mesothelial cells are activated to proliferate extensively to 
repair the lesion (reviewed by (Herrick and Mutsaers, 2004)) and the existence of 
Figure 1: Anatomy of the pleura. 
Adapted from 
www.virtualmedicalcenter.com. 
Figure 2: The five layers of the 
pleura. A histological view. 
Adapted from Murali, 2010. 
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rare cells with progenitor-cell characteristics within normal mesothelial cells have re-
cently been described (Lansley et al., 2010). 
3.1.3 PLEURAL EMBRYOGENESIS 
Mesothelial cells derive from embryonic mesodermal cells, where they develop from 
the coelomic cavity during early embryogenesis (Murali et al., 2010). From the neural 
groove the intraembryonic mesoderm differentiates on each side into paraxial, inter-
mediate and lateral mesoderm (Herrick and Mutsaers, 2004). Later the intraembryon-
ic somatic or parietal layer and the intraembryonic splanchnic or visceral layer form, 
which takes place after spaces appear in the lateral mesoderm fused and divided the 
mesoderm in these two layers (Herrick and Mutsaers, 2004). Next the somatopleure 
(embryonic body wall) is formed by the somatic mesoderm together with the embry-
onic ectoderm (Herrick and Mutsaers, 2004). On the other hand the splanchnopleure 
(embryonic gut wall) is formed by the splanchnic mesoderm together with the embry-
onic ectoderm (Herrick and Mutsaers, 2004). By extending the somatopleure as well 
as the splanchnopleure along the embryonic length and fusing ventrally creates the 
intraembryonic coelum which represents a primitive body cavity (Wang, 1998). Later 
the splanchnopleure will form the viscera and heart as well as the visceral pleura 
(Herrick and Mutsaers, 2004), (Wang, 1998). The somatopleure will form the body 
wall lining and dermis as well as the parietal pleura (Herrick and Mutsaers, 2004), 
(Wang, 1998). 
It was shown that epithelial cells of the coelomic wall express podoplanin which later 
line the pleural cavity (Gittenberger-de Groot et al., 2007), (Mahtab et al., 2008). 
Podoplanin expression is important during embryogenesis, because it was observed 
that knocking down podoplanin in mouse embryos lead to embryonic and fetal death 
at stages E10 – E16 as well as to neonatal death within the first weeks of life (Mahtab 
et al., 2008). Podoplanin expression in peritoneal mesothelial cells was for the first 
time observed in 1997 (BreitenederGeleff et al., 1997). Hence podoplanin might rep-
resent a marker for the coelomic mesothelium, which is maintained in some adult 
mesothelial cells with precursor properties. 
Additionally, coelomic epithelium during embryogenesis also expresses Wilms tumor 
gene WT1 (summarized by (Moore et al., 1999)). It is suggested that WT1 plays a 
role in epithelial-to-mesenchymal transition (EMT) during embryogenesis (summa-
rized by (Moore et al., 1999)) since down-regulation of WT1 is associated with EMT 
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(Wilm et al., 2005). The first WT1 expression during embryogenesis is observed at 
E9 (days post coitum)2 in the region of developing heart (Moore et al., 1999) and 
WT1 null mice die with malformed heart at midgestation (Moore et al., 1999). WT1 is 
then expressed throughout embryogenesis and adulthood in the serosal mesothelium 
(Wilm et al., 2005). 
3.1.4 FUNCTION OF THE PLEURA 
The mesothelium provides many different, essential functions. By secreting glycosa-
minoglycans (GAGs) it provides a slippery surface to minimize the friction during 
breathing which is essential for the lung to work properly. The amount of this so 
called pleural fluid in healthy tissues is around 0.1 – 0.2 ml/kg body weight (Murali et 
al., 2010). For the homeostasis of the pleural fluid, the lymphatic system is of great 
importance. In the caudal portion of the parietal pleura, pores called stomata, con-
nect the pleural space to the lymph, allowing accumulating fluid and inflammatory 
cells to be removed into the lymphatic system (English and Leslie, 2006). 
The slippery surface also protects the pleura from infections as well as tumor dissem-
ination (Herrick and Mutsaers, 2004), most probably in a way that cells, bacteria do 
not adhere to the mesothelium. Additionally, mesothelial cells secret various media-
tors (i.e. growth factors and cytokines) to modulate and participate inflammation and 
which help trafficking leukocytes across the pleural space (Herrick and Mutsaers, 
2004). Furthermore, upon stimuli like tissue injury, asbestos and bacterial products, 
mesothelial cells produce different cytokines resulting in a pro- or anti-inflammatory 
response helping to regulate the inflammatory response. Additionally, growth factors 
produced by mesothelial cells help to stimulate cell proliferation, differentiation and 
migration of themselves to sides of tissue injury therefore stimulating tissue repair 
(Herrick and Mutsaers, 2004).  
3.1.5 ASBESTOS 
Asbestos is a naturally occurring silicate mineral fiber extremely heat persistent and 
flexible (Yang et al., 2008), (Donaldson et al., 2010), (Donaldson, 2009). Therefore it 
was used due to its softness and flexibility in many fields to make each material more 
fire persistent (i.e. curtains, fire protecting cloths, in brakes as well as in military 
masks) (Alleman and Mossman, 1997), (Yang et al., 2008). 
                                            
2 Age of an embryo 
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Asbestos is divided into two forms: the serpentines (including chrysotile, the white 
asbestos, Figure 3) and amphiboles (including crocidolite, the blue asbestos and 
amosite, the brown asbestos, Figure 3). Crocidolite and amosite are the most com-
mon amphiboles with crocidolite to be the most dangerous form due to its long and 
thin fiber shape. Nevertheless, chrysotile was the form mostly in use (95% of used 
asbestos in the world). It is not as dangerous as amphiboles due to its softer struc-
ture which can be broken down by the body. 
 
 
 
 
 
 
 
 
 
 
Figure 3: Asbestos fibers representing chrysotile (white), crocidolite (blue), amosite 
(brown) asbestos. Science photo library, Dr. Jeremy Burgess and Power and Syred, 
(www.sciencephoto.com). 
 
3.1.6 ASBESTOS CLEARANCE 
Dependent on its aerodynamic diameter, inhaled particles can be cleared from the 
respiratory tract at different deposition sites (Lippmann et al., 1980). Soluble particles 
are most likely taken up systemically at all deposition sites (Lippmann et al., 1980). 
Particles which are slowly soluble are transported from the deposition site in the con-
ducting airways to the glottis3 to be swallowed (Lippmann et al., 1980). Insoluble par-
ticles with large surface-to-volume ratios can deposit in non-ciliated airways and may 
be cleared by dissolution (Lippmann et al., 1980). Additionally they can be cleared as 
free particles or they are phagocytosed and transported by alveolar macrophages 
(Lippmann et al., 1980). Particles reaching the epithelium either as free particles or 
                                            
3 Combination of the vocal folds and the space in between the folds 
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within macrophages are either discharged within cells or might reach the pleura as 
well as lymph nodes (Lippmann et al., 1980). 
The toxic characteristics of inhaled fibers is most importantly their geometry not their 
chemical composition (Donaldson et al., 2010). Chemical composition only plays a 
role concerning its biopersistence (Donaldson et al., 2010). Therefore, the fiber path-
ogenicity paradigm claims that a long, thin and biopersistent fiber is pathogenic 
(Donaldson et al., 2010). Because the fibers are so long macrophages undergo frus-
trated phagocytosis, a process in which macrophages fail to completely enclose long 
fibers (Figure 4) (Donaldson et al., 2010). Frustrated phagocytosis is a pro-
inflammatory process releasing oxidants and cytokines and therefore probably partic-
ipates in mesothelioma development. 
 
 
 
 
 
 
 
 
 
 
Furthermore, asbestos fibers reaching the pleura as free particles might depose at 
parietal stomata (pore like structure < 10m), because they are too long to pass 
through to reach the lymph system (illustrated in Figure 5, (Donaldson et al., 2010)). 
Accumulated asbestos fibers at the stomata attract macrophages (Yang et al., 2008) 
leading to frustrated phagocytosis (Donaldson et al., 2010). 
Nevertheless, as Cugell already stated: “how asbestos fibres…migrate to the pleura 
surface…is quite obscure.” (Cugell and Kamp, 2004). 
 
 
 
 
 
 
Figure 4: Illustration of frus-
trated phagocytosis, right pan-
el leading to inflammation. Left 
panel illustrates normal phag-
ocytosis leading to clearance. 
Adapted from Donaldson, 
2010. 
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Figure 5: Hypothesized asbestos fibers retention at stomata leading to inflammation. 
Adapted from Donaldson, 2010. 
 
3.1.7 MESOTHELIOMA CARCINOGENESIS 
Upon asbestos deposition in the pleura and frustrated phagocytosis, macrophages 
release tumor necrosis factor-alpha (TNF-) (Yang et al., 2008). Simultaneously, it 
initiates mesothelial cells to express TNF-R1, the TNF- receptor at its cell mem-
brane (Yang et al., 2008). Additionally, mesothelial cells start to release TNF- in a 
paracrine and autocrine manner (Yang et al., 2008). TNF- binding to its receptor 
expressed by mesothelial cells, induces the NF-B pathway resulting in a better sur-
vival of mesothelial cells upon asbestos exposure (Yang et al., 2008). Also other 
growth factors and cytokines are released like transforming growth factor beta (TGF-
), insulin-like growth factor (IGF), interleukins 6 and 8 (IL-6/-8) and some more 
(Yang et al., 2008), (Yao et al., 2010). 
Furthermore, asbestos fibers (with a certain iron content) induce DNA damage in 
mesothelial cells via free radicals (iron-catalyzed) which produce DNA strand breaks 
(Cugell and Kamp, 2004), (Yang et al., 2008). Further, mutations like base substitu-
tions, deletions and rearrangements and sister chromatin exchange are caused by 
reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) released up-
on asbestos exposure (Yang et al., 2008). The increased survival of mesothelial cells 
induced by TNF- and the NF-B pathway in combination with accumulated DNA 
Parietal pleura 
Visceral pleura 
Pleural space 
Pleural space 
Parietal pleura with stomata 
leading to lymph channels 
Small particles pass through stomata into the 
lymph 
Asbestos fibres do not pass through stomata, 
retaining at the opening and inducing inflam-
mation leading to pleural pathology 
Sub-pleural 
alveolus 
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damages leads to carcinogenic transformations of mesothelial cells and further to 
mesothelioma (Yang et al., 2008), (Yao et al., 2010). 
Upon mutations caused by asbestos fibers, chromosomal regions harboring tumor 
suppressor genes are deleted or inactivated. In mesothelioma the most commonly 
observed chromosomal change (40%) takes place on chromosome 22q12 where the 
neurofibromatosis type 2 (NF2) gene is located and which encodes the tumor sup-
pressor merlin (Thurneysen et al., 2009). NF2 is thought to be a ‘gatekeeper’ in mes-
othelioma induced by asbestos, because it was shown that upon deletion of one al-
lele in mice, the frequency of tumor development after asbestos exposure increased 
compared to wild–type mice (reviewed by (Stahel et al., 2009)) and additionally these 
mice lost their second allele of NF2 (reviewed by (Stahel et al., 2009). A second re-
gion also often deleted or inactivated in mesothelioma locates at chromosome 9p21 
including the gene INK4/ARF which encodes p16(INK4A) and p14(ARF) (Stahel et 
al., 2009), (Yang et al., 2008). P53 deletion or inactivation is only occasionally ob-
served in mesothelioma (Yang et al., 2008). 
Deletion and/or inactivation of NF2 increases cyclin D1 expression driving cells to 
enter S-phase (Xiao et al., 2005) and which leads to increased proliferation. Deletion 
and/or inactivation of p16(INK4a) encoding a cyclin-dependent kinas inhibitor, and 
p14(ARF), encoding a component of the p53 cell cycle checkpoint, results in impaired 
retinoblastoma (Rb) and p53 pathways (Yang et al., 2008). 
3.1.8 DIAGNOSIS OF MALIGNANT PLEURAL MESOTHELIOMA 
Due to its long latency time, patients most commonly are 50 to 70 years old. They 
suffer from dyspnea4, coughing and chest pain or both (Moore et al., 2008). In rare 
cases sweating, weight loss and chest wall mass occur (Moore et al., 2008). Further 
signs of mesothelioma are pleural effusion, fatigue, wheezing, blood in the fluid 
coughed up, pneumothorax5 or even collapse of the lung. In a later stage also dys-
phagia6 occurs (Moore et al., 2008). 
For diagnosis and staging of mesothelioma radiological and pathological technics are 
used. Radiology includes X-ray, computer tomography (CT), magnetic resonance 
imaging (MRI) and positron emission tomography (PET) (Moore et al., 2008). The 
radiological technique which is used first in MPM diagnosis is the intravenous con-
                                            
4 Shortage of breath 
5 Collection of air in the pleural cavity 
6 Symptom of difficulty in swallowing 
15 
 
trast-enhanced CT scan (Moore et al., 2008). It has the advantage of visualizing the 
whole pleural surface including the diaphragm (Moore et al., 2008). CT scans are 
helpful in diagnosing MPM with results as 1) a circumferential pleural rind, 2) nodular 
pleural thickening, 3) pleural thickening of > 1 cm and 4) mediastinal pleural involve-
ment (Moore et al., 2008). Nevertheless, absence of these findings does not exclude 
diagnosis of mesothelioma (Moore et al., 2008). 
MRI for mesothelioma diagnosis is not routinely used (Moore et al., 2008). It is helpful 
to investigate tumor spreads into the diaphragm or chest wall to make better estima-
tion before surgery (Moore et al., 2008). 
PET scans are used to distinguish benign from malign pleural diseases (Moore et al., 
2008). Therefore a sub-variant of PET, the standardized uptake value (SUV) PET is 
used, because it is a semi-quantitative measurement of a lesion’s metabolic activity 
which is higher in mesotheliomas than in benign pleural diseases (Moore et al., 
2008). Due to its metabolic and anatomical information PET scans are helpful for 
staging mesothelioma (Moore et al., 2008). 
Diagnosis and staging should not only rely on different radiological methods but 
should be combined with pathological investigations (van Meerbeeck et al., 2011). 
Ideally a biopsy specimen of MPM should be used and investigated by immunohisto-
chemistry and microscopy (van Meerbeeck et al., 2011). Best immunohistochemical 
markers to identify MPM are cytokeratin 5/6, calretinin, podoplanin and WT1 (Husain 
et al., 2009), (Mutsaers, 2002). It is also recommended to include negative markers. 
To distinguish MPM from other malignancies of the thorax like lung adenocarcinoma 
and squamous carcinoma markers which are differentially expressed between the 
malignancies are used such as MOC-31 and CEA for lung adenocarcinoma or p63 
and MOC-31 for squamous carcinoma (Husain et al., 2009). 
A very crucial issue in diagnosing and staging mesothelioma is the identification of 
mesothelioma’s histotype (Husain et al., 2009). Mesothelioma can be sub-divided 
into epithelioid, sarcomatoid and biphasic mesothelioma (Husain et al., 2009). The 
histology of epithelioid MPM includes cells of cuboidal, polygonal or oval shape mim-
icking normal mesothelial cells (Husain et al., 2009). On the other hand, the histology 
of sarcomatoid MPM includes cells of spindle like morphology (Husain et al., 2009). 
The biphasic histotype includes epithelioid as well as sarcomatoid parts in the same 
tumor (Husain et al., 2009). Patients diagnosed with sarcomatoid mesothelioma have 
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worst prognosis (Belli et al., 2009), (Stahel and Weder, 2009), (Sugarbaker and 
Norberto, 1998). 
Staging after diagnosis should be done according to the international mesothelioma 
interest group (IMIG) TNM staging system (Appendix 1, (Moore et al., 2008), 
www.imig.org). 
3.1.9 TREATMENT OF MALIGNANT PLEURAL MESOTHELIOMA 
In general the treatment of patients diagnosed with malignant pleural mesothelioma 
is controversial and depending on the fitness of a patient to undergo surgery. 
Surgery, even though controversial for MPM treatment (Kaufman and Flores, 2011), 
is aimed at resection the tumor bulk as well as for diagnostic purposes. To achieve a 
biopsy for diagnosis a thoracoscopy is performed (Stahel and Weder, 2009). Further, 
for resection of tumor bulk either pleurectomy/decortication or a more radical method 
extrapleural pneumonectomy (EPP) is used (Stahel and Weder, 2009). Still debates 
are ongoing which method is the best for resection (Stahel and Weder, 2009). The 
milder pleurectomy/decortication (P/D) involves the removal of the parietal pleura 
including parts of the mediastinum, pericardium and diaphragm together with decorti-
cation of the lung by stripping off the visceral pleura (Ismail-Khan et al., 2006). Unfor-
tunately in almost 80% of P/D, small tumor bulk is left in leading to recurrence in up 
to 90% of cases (reviewed by (Ismail-Khan et al., 2006). EPP on the other hand is a 
more radical method which removes altogether the visceral and parietal pleura to-
gether with the affected lung diaphragm, pericardium and mediastinal lymph nodes 
and the lung leading to severe physiological consequences for the patient (reviewed 
in (Stahel and Weder, 2009)). Due to its severity, EPP is not suitable for every patient 
and they have to pass pivotal selection criteria. 
The preferred systemic chemotherapy for mesothelioma treatment is the combination 
of pemetrexed and cisplatin, because it showed superiority concerning treatment re-
sponse and median survival of the patients compared to a single agent used for 
treatment (Stahel and Weder, 2009). Another combined chemotherapy with rather 
palliative effect is the use of mitomycin C, vinblastine and cisplatin. Further, cisplatin 
was combined with carboplatin or gemcitabine, where no better efficacy was ob-
served (reviewed by (Stahel and Weder, 2009)). 
Multimodality therapy was initially performed with the idea to reduce local and distant 
relapses by combining chemo- or radiotherapy to surgery (Sugarbaker and Norberto, 
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1998). It includes neoadjuvant chemotherapy, a pre-treatment of the patient with 
therapeutic agents before starting the main treatment, together with EPP (reviewed 
by (Stahel and Weder, 2009)). This multimodality therapy increased median survival 
of MPM patients up to 23 months in Zurich and up to 19.2 months in the US (re-
viewed by (Stahel and Weder, 2009)). 
To further improve MPM treatment research recently focuses on the identification of 
signaling pathways to develop targeted therapies. A signal pathway deregulated in 
cells leading to tumor growth and progression is the one induced by growth factors 
binding to receptor tyrosine kinases (TRK) (Belli et al., 2009), (van Meerbeeck et al., 
2011). Under normal conditions the receptor tyrosine kinase pathway regulates cell 
proliferation, survival, cell movement and chemoresistance (Belli et al., 2009). TRK 
gets activated upon growth factor binding such as epidermal growth factor (EGF), 
vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), 
insulin growth factor (IGF) or transforming growth factor  (TGF-, where the latter 
binds to serine/threonine kinase receptors. It was observed that EGFR is overex-
pressed in MPM (reviewed by (Belli et al., 2009) and (van Meerbeeck et al., 2011)). 
Therefore gefitinib, an EGFR tyrosine kinase inhibitor, was investigated regarding its 
role in MPM treatment in a phase II clinical trial (reviewed by (Belli et al., 2009) and 
(van Meerbeeck et al., 2011)). Unfortunately no objective response was observed; 
therefore it was not further investigated (Belli et al., 2009), (van Meerbeeck et al., 
2011). For a second EGFR inhibitor, erlotinib, evaluated in a phase II clinical trial, 
similar results were obtained (Belli et al., 2009), (van Meerbeeck et al., 2011). The 
observed un-responsiveness of EGFR tyrosine kinase inhibitors (EGFR-TKIs) might 
be explained by the absence of activating somatic mutation in EGFR-TKI domain 
which is strongly predictive of response to EGFR-TKIs as stated by reviewers (Belli et 
al., 2009), (van Meerbeeck et al., 2011). VEGF performing autocrine signaling during 
MPM development, was inhibited using a monoclonal antibody, bevacizumab (Belli et 
al., 2009), (van Meerbeeck et al., 2011). In a randomized phase II clinical trial 
bevacizumab was administered alone or in combination with cisplatin and gemcita-
bine (Belli et al., 2009), (van Meerbeeck et al., 2011). Also in this clinical trial no sig-
nificant improvement in the outcome was observed (Belli et al., 2009), (van 
Meerbeeck et al., 2011). 
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3.2 THE CANCER STEM CELL THEORY 
Somatic stem cells or tissue stem cells are cells with self-renewal potential and the 
capacity to differentiate into progenitor cells leading to the heterogeneity of cells with-
in a tissue/organ (Reya et al., 2001). These characteristics are necessary to keep a 
tissue intact over a lifespan. Indeed, somatic stem cells are activated upon injury to 
repair lesions or are responsible for the renewal of the tissue by differentiation into 
fast proliferating progenitor cells, and to self-renew to keep the stem cell pool con-
stant. Stem cells are a rare population within a tissue (Reya et al., 2001). Most stem 
cells are tissue specific, even though it could be observed that hematopoietic stem 
cells could differentiate into cells of non-hematopoietic tissues (Petersen et al., 1999). 
The best studied stem cells are the hematopoietic stem cells differentiating into all 
the cells of the blood system. 
It seems that stem cell biology and tumor biology shares some aspects. Stem cells 
as well as tumor cells proliferate and differentiate to built-up/renew either an or-
gan/tissue or a tumor bulk, respectively. Since stem cells are alive for a lifespan (due 
to their self-renewal capacity), the probability of accumulating mutations in stem cells 
leading to transformation into cancer (stem) cells (Reya et al., 2001) is increased. 
Due to this potential parallel between stem cell and tumor biology, a new model has 
been developed over the last decades to explain tumor growth. This so called cancer 
stem cell model (Figure 6B) claims that only few cells within a heterogeneous tumor 
are able to proliferate extensively and give rise to new tumors (Reya et al., 2001). 
The bulk tumor cells of this model have limited proliferation potential compared to the 
so called cancer stem cells (Reya et al., 2001). On the other hand the older, clonal 
evolution model (Figure 6A) claims that in a heterogeneous tumor each cell has the 
potential to proliferate extensively, but the probability of a single cell to proliferate ex-
tensively within a tumor is very low (Reya et al., 2001). 
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Figure 6: Two models explaining tumor growth. A) In the clonal evolution model each 
cell has the potential to proliferate extensively, but with only very low probability. B) In 
the cancer stem cell mode, only a minority of cells, the CSC proliferate extensively to 
built-up the whole tumor. Adapted from Reya et al. 2001. 
 
The cancer stem cell model not only explains the growth of tumors, but also explains 
why tumors after their resection, chemotherapy and/or radiotherapy re-grow. Cancer 
treatment targets mainly bulk tumor cells leading to tumor shrinkage, but leaves can-
cer stem cells unharmed (Figure 7) (Reya et al., 2001). Additionally, it is speculated 
that due to drug transporter expression at the cell surface of cancer stem cells, they 
are more resistant against chemotherapeutics (Reya et al., 2001). The remaining vi-
able cancer stem cells then lead to regrowth of the tumor.  
 
 
 
 
 
 
 
 
 
Figure 7: Targeting tumor bulk cells with chemotherapy shrinks the tumor, but it will 
regrow. Targeting cancer stem cells with chemotherapy will defeat the tumors ability 
of regrowth. Adapted from Reya, 2006. 
 
A B 
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3.2.1 LEUKEMIA INITIATING CELLS 
Indications for the cancer stem cell model came from Lapidot et al. in 1994 (Lapidot 
et al., 1994). They suggested that in human acute myeloid leukemia (AML) a proba-
ble rare leukemia stem cell exists, because most AML cells are limited in their prolif-
erative capacity (Lapidot et al., 1994). AML cells were sorted according to the ex-
pression of the cell surface marker CD34, usually expressed by pluripotent stem cells 
and progenitor cells of the bone marrow. After transplantation of CD34+ and CD34- 
AML cells into SCID mice, only CD34+ cells were able to engraft the mice (Lapidot et 
al., 1994). Then cells were sorted according to the expression of CD38 on CD34+ 
cells. CD38 expressed by CD34+ cells indicates their commitment for lineage. There-
fore CD34+CD38- AML cells specify an immature cell of the bone marrow (Lapidot et 
al., 1994). Also here, these CD34+CD38- cells could engraft SCID and NOD/SCID 
(Bonnet and Dick, 1997) mice after transplantation whereas CD34+CD38+ cells were 
not able to do so (Bonnet and Dick, 1997), (Lapidot et al., 1994). Bonnet and Dick 
additionally showed that CD34+CD38- cells in NOD/SCID mice reproduced the dis-
ease of the patient, indicating their capacity to differentiate (Bonnet and Dick, 1997). 
Furthermore they showed that these cells could self-renew in mice after re-
engraftment of the donor’s disease in second generation mice (Bonnet and Dick, 
1997). All these findings indicate a hierarchical organization of AML (Bonnet and 
Dick, 1997) from where the cancer stem cell model developed. 
Moreover, Costello et al. (Costello et al., 2000) showed in AML that the leukemia ini-
tiating cells CD34+CD38- had a lower daunorubicin accumulation compared to 
CD34+CD38+ cells (Costello et al., 2000). Chemosensitivity of these cells against 
daunorubicin was tested and observed that CD34+CD38- cells were higher proliferat-
ing after daunorubicin treatment compared to CD34+CD38+ cells (Costello et al., 
2000). The increased proliferation rate accompanied by decreased apoptosis upon 
daunorubicin treatment and increased MRP expression, an ABC transporter well-
known to efflux daunorubicin (Costello et al., 2000). Thereafter authors concluded 
CD34+CD38- cells to be the immature leukemic progenitors with increased chemo-
therapeutic resistance. 
3.2.2 CANCER STEM CELLS IN SOLID TUMORS 
Almost 10 years after the identification of cancer stem cells in AML, Al-Hajj et al. (Al-
Hajj et al., 2003) presented the first CSCs in a solid tumor. In their study, they inves-
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tigated breast cancer for the presence of CSCs. For this purpose, authors considered 
the well-known heterogeneous expression of CD44 and CD24 (two adhesion mole-
cules) to potentially differentiate tumorigenic from non-tumorigenic cells. By sorting 
breast cancer cells (from patients as well as passaged one to two times in mice) ac-
cording to their expression of CD44, CD24 and Lineage cell surface markers, and 
after their injection into NOD/SCID mice, they identified CD44+CD24-Lineage- cells to 
be more tumorigenic in vivo compared to CD44+CD24+Lineage- cells (Al-Hajj et al., 
2003). Additionally, they observed the self-renewal capacity of CD44+CD24-Lineage- 
cells in vivo giving rise to both tumorigenic CD44+CD24-Lineage- and non-
tumorigenic CD44+CD24+Lineage- cells in second generation mice (Al-Hajj et al., 
2003) recapitulating the heterogeneity of the tumor they derived from. This observa-
tion could not be made for the CD44+CD24+Lineage- cells. Finally authors claimed 
that breast cancer is also hierarchically organized, because early multipotent epithe-
lial progenitor cells also do express CD44 (Al-Hajj et al., 2003). 
In the same year, Singh et al. identified in 4 phenotypic different brain tumors the 
brain tumor stem cells which were in an undifferentiated state, not expressing differ-
entiation markers (-tubulin 3 for neurons and GFAP for astrocytes) (Singh et al., 
2003). Nevertheless these brain tumor stem cells were characterized by the expres-
sion of the neural stem cell surface marker CD133 (prominin-1). CD133+ brain tumor 
cells exhibited increased self-renewal as well as proliferating capacity compared to 
CD133- brain tumor cells in a sphere formatting assay (Singh et al., 2003). Further-
more, CD133+ cells recapitulated the tumor they derived from (Singh et al., 2003). 
Unfortunately it later became clear that CD133 as a sole marker to identify CSCs in 
glioma is not enough (Campos and Herold-Mende, 2011), because it was observed 
that CD133 positive as well as negative cells induced tumor growth in vivo (Shmelkov 
et al., 2008). 
From then on in many solid tumors cancer stem cells were identified according to 
corresponding tissue stem cell markers, reviewed in Visvader & Lindeman (Visvader 
and Lindeman, 2008) and Cho & Clarke (Cho and Clarke, 2008). 
3.2.3 FUNCTIONAL ASSAYS TO IDENTIFY CANCER STEM CELLS 
The cancer stem cell model claims that mutated somatic stem cells are the source of 
tumor growth/relapse (see section 3.2). Hence, it is possible to use known stem cell 
surface markers to isolate putative cancer stem cells and investigate their capaci-
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ty/potency of tumor initiation, self-renewal and differentiation. In tissues, in which no 
stem cell surface markers have been identified to date, such an approach is not pos-
sible. Therefore, another approach would be to investigate functional markers of stem 
cells which are kept by transformed cancer stem cells as suggested by Ginestier et 
al. (Ginestier et al., 2007). To date, two functional assays developed to identify so-
matic and cancer stem cells: the aldehyde dehydrogenase assay (section 3.2.3.1) 
and the side population assay (3.2.3.2). 
3.2.3.1 THE ALDEHYDE DEHYDROGENASE ASSAY 
Aldehyde dehydrogenase 1 is a cytosolic enzyme expressed by the ALDH1 gene. 
This enzyme oxidizes intracellular aldehydes and therewith detoxifies aldehydes 
(Ginestier et al., 2007). ALDH1 was observed to be highly expressed in hematopoiet-
ic stem cells most probably to protect the cells from toxic aldehydes.  
ALDH positive cells can be isolated using flow cytometer technics. Therefore cells 
are probed with a fluorescent aldehyde substrate (BAAA, BODIPY – aminoacetalde-
hyde) which diffuses across the cell membrane of living cells (Storms et al., 1999), 
(Storms et al., 2005). The substrate gets oxidized by aldehyde leading to a fluores-
cent product staying within the cell (negatively charged BAA-, BODIPY – aminoace-
tate). It then can be excited at 488 nm and the emission of which can be detected 
with a 530/30 band pass filter in a flow cytometer and/or sorted by FACS (StemCell 
Technologies), (Storms et al., 1999), (Storms et al., 2005). Data are analyzed in a 
dotplot (SSC vs. BODIPY) and cells would be sorted according to their BAAA signal 
with potential stem cells isolated from a SSCloALDHbr gate (SSC low and ALDH 
bright; Figure 8), because cells with high aldehyde activity, the potential cancer/tissue 
stem cells, stain brighter than cells with less activity.  
 
 
 
 
 
 
 530/30 
Figure 8: Representative flow 
cytometery analysis using the 
aldehyde dehydrogenase as-
say. Green: SSCloALDHbr 
cells. Adapted from StemCell 
Technologies. 
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3.2.3.2 THE SIDE POPULATION ASSAY 
Another functional assay, called side population assay was developed by Goodell et 
al. in 1996 (Goodell et al., 1996). By using the DNA staining dye Hoechst 33342 to 
mark living cells of the whole murine bone marrow, they identified a so called side 
population (SP) after exciting Hoechst 33342 at 350 nm (UV light) and detection of its 
emission at two different wavelengths: Hoechst red (675 nm long pass filter) and 
Hoechst blue (450/20 nm band pass filter) (Goodell et al., 1996). This detection strat-
egy of Hoechst leads to a better separation of its signal. This is of need, because 
Hoechst has a very broad emission spectrum ranging from 400 – 600 nm (Watson et 
al., 1985). A second DNA dye in use to detect SP cells is DyeCycleViolet (Mathew et 
al., 2009), (She et al., 2008), (Telford et al., 2007). It shares emission and cell per-
meability characteristics with Hoechst 33342 (reviewed by (Telford et al., 2007)). The 
advantage of DCV is its longer excitation wavelength (369 nm, (Telford et al., 2007)). 
Exciting DCV at 405 nm reveals emission of 20%, whereas Hoechst excited at 405 
nm reveals only 5% emission (Telford et al., 2007). This is of importance, because 
most flow cytometers and FACS machines are only equipped with a 405 nm laser, 
not with a UV laser actually needed to excite Hoechst and DCV best. 
Goodell et al. characterized the SP cells of whole murine bone marrow according to 
their expression of cell surface markers as Sca-1+Linneg/low cells, representing the mu-
rine HSCs (Goodell et al., 1996). Additionally these SP cells were enriched for stem 
cell activity in vivo and contributed to both lymphoid and myeloid lineages in vivo 
(Goodell et al., 1996). 
This functional assay is based on the expression of drug transporters in the cell 
membrane of cancer/tissue stem cells. The drug transporters efflux substrates like 
DNA staining dyes. Therefore, cells are stained with Hoechst 33342 or DCV in the 
presence or absence of a drug transporter inhibitor. The side population is defined in 
the lower left corner of the dotplot analysis (Hoechst/DCV red vs. blue), representing 
cells which efflux the DNA dyes, so-called Hoechst/DCV low cells. By comparing dot-
plots of minus inhibitor treated samples to plus inhibitor treated samples, the side 
population is precisely defined as the population disappearing in inhibitor treated 
samples (Supplementary Figure 1 and Figure 9). 
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Figure 9: Flow cytometry dotplot analysis. Side population is indicated with the 
arrow (A), which disappears in the presence of the drug transporter inhibitor 
(B). Adapted from Goodell 1996. 
 
3.2.4 ABCG2 EXPRESSING SIDE POPULATION CELLS IN NORMAL TISSUE 
Already Goodell et al. stated that the responsible factor for the side population phe-
notype observed might be a drug transporter like MDR/p-glycoprotein belonging (like 
MRP) to the ABC drug transporter family and which efflux Hoechst 33342 leading to 
the Hoechst 33342 low (i.e. SP) profile in a flow cytometry analysis (Figure 9) 
(Goodell et al., 1996). To shed light on the transporters expressed in SP cells, Zhou 
et al. investigated the SP in bone marrow cells of MDR1 knock-down mice and ob-
served that knocking down MDR1 does not abolish the SP fraction (Zhou et al., 2001) 
indicating that MDR1 is not the ABC transporter responsible for the SP phenotype. 
Nevertheless a different ABC transporter was responsible for this phenotype since 
ATP depletion as well as the incubation with a functional inhibitor of several ABC 
transporters diminished the SP fraction in these MDR1 knock-down mice (Zhou et al., 
2001). In their study ABCG2, another ABC transporter, was identified to be highly 
expressed in SP cells as well as in CD34- murine bone marrow stem cells (including 
hematopoietic, mesenchymal and endothelial cells) (Zhou et al., 2001). In addition, 
higher expression of ABCG2 was observed in SP cells of rhesus monkey bone mar-
row and mouse skeletal cells compared to non-SP (NSP) cells (Zhou et al., 2001). 
Furthermore, overexpression of ABCG2 in hematopoietic stem cells inhibited their 
differentiation (Zhou et al., 2001). Scharenberg et al. (Scharenberg et al., 2002) also 
identified ABCG2 to be the drug transporter responsible for the side population phe-
- inhibitor + inhibitor 
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notype in hematopoietic stem cells. This was confirmed in a later study of Zhou et al. 
(Zhou et al., 2002) where they correlated K+S+L- hematopoietic stem cells with 
ABCG2 expressing SP cells with in vivo repopulating capacities. 
SP cells harboring putative tissue stem cells were identified for multiple different tis-
sues like in skeletal muscle (Montanaro et al., 2004), mammary glands (Welm et al., 
2002), testis (Lassalle et al., 2004) and limbal7 epithelium (Watanabe et al., 2004). 
3.2.5 ABCG2 EXPRESSING SIDE POPULATION CELLS IN CANCERS 
Beside the fact that murine bone marrow includes a SP fraction with stem cell activity 
and potency (Goodell et al., 1996) and CD34+CD38- AML initiating cells do so as well 
(Bonnet and Dick, 1997), (Lapidot et al., 1994), Wulf et al. (Wulf et al., 2001) next 
detected in the bone marrow and the peripheral blood of acute myeloid leukemia pa-
tients SP fractions with leukemia initiating potential. Later on, SP fractions with in-
creased in vivo tumorigenic potential were detected in cell cultures or tissues derived 
from different solid tumors. Kondo et al. (Kondo et al., 2004) isolated from C6 glioma 
cell lines SP cells with characteristics of multipotent cancer stem cells in vivo. Sorted 
SP cells had increased tumor growth potency compared to NSP cells in vivo and tu-
mors developed from C6 glioma SP cells expressed neuron and glia cell markers 
suggesting the differentiation capacity of SP cells in vivo (Kondo et al., 2004). Fur-
ther, Hirschmann-Jax et al. identified in neuroblastoma samples SP cells with in-
creased in vitro proliferation and self-renewal potential (Hirschmann-Jax et al., 2004). 
In the meanwhile SP cells with cancer stem cell/tumor initiating characteristics were 
identified in ovarian cancer (Szotek et al., 2006), lung cancer (Ho et al., 2007), 
(Loebinger et al., 2008), hepatocellular carcinoma (Chiba et al., 2006), nasopharyn-
geal carcinoma (Wang et al., 2007), bone sarcomas (Murase et al., 2009), pancreatic 
carcinoma (Wang et al., 2009) and in glioblastoma (Fukaya et al., 2010). 
 
3.3 THE ABCG2 DRUG TRANSPORTER 
3.3.1 ATP-BINDING CASSETTE TRANSPORTERS 
The ABCG2 drug transporter responsible for the SP phenotype is a member of the 
ATP-binding cassette transporter family, the biggest family of active transporters (49 
                                            
7 Border of the cornea (transparent front part of the eye covering the iris and pupil) and the white of the 
eye 
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members identified so far, (Matsson et al., 2011)). In eukaryotic cells they are always 
efflux pumps, exporting substrates across the cell membrane and against a concen-
tration gradient. Therefore in almost all cases it is an energy dependent step 
(Scharenberg et al., 2002) using ATP-binding and its hydrolysis as source of energy 
(Robey et al., 2009). Beside the role of ABCG2 in the SP phenotype, ABCG2 togeth-
er with the multidrug resistance protein, p-glycoprotein ABCB1 (P-gp/MDR-1) and the 
multidrug resistance-associated protein-1 ABCC1 (MRP-1) (Robey et al., 2009), 
(Scharenberg et al., 2002), they are frequently associated with the multidrug re-
sistance phenotype observed in cancer cells. The overexpression of these drug 
transporters protects cancer cells against chemotherapeutics via increased drug ef-
flux decreasing intracellular drug concentrations (Robey et al., 2009). 
Alterations in ABC drug transporter expression, most probably due to mutations, are 
not only observed in cancers leading to chemoresistance, but also in many other dis-
eases: ABCG5 and/or ABCG8 are mutated in sitosterolemia8 or ABCA1 is mutated in 
high-density lipoprotein deficiency (Tangier disease) (Matsson et al., 2011), 
(Velamakanni et al., 2007). 
ABC drug transporters in general have a structure including a pair of transmembrane 
(TM) domains which are hydrophobic and give most of its specificity to the trans-
porter. Further, they include a set of two ATP-binding domains (or nucleotide-binding 
folds, NBFs) (Robey et al., 2009) according to their sequence, the transporters are 
grouped into subfamilies (A-G in the human genome). While most genes encode full 
transporters, the G subfamily encodes only half-transporters which have to dimerize 
or maybe also oligomerize as homo- or heterodimers to acquire its full activity (see 
Oligomerization section 3.3.2.4) (Robey et al., 2009). 
3.3.2 ABCG2 
Initially, ABCG2 was identified as a drug transporter responsible for the multidrug 
resistance observed in cancer cells. Before the association of ABCG2 with the multi-
drug resistance phenotype of cancer cells, Pgp and MRP were known drug trans-
porters responsible for this phenotype. Nevertheless, Doyle et al. investigated the 
multidrug resistant breast cancer cell line MCF-7/AdrVp, which was known not to 
overexpress Pgp or MRP (Doyle et al., 1998). By RNA fingerprinting Doyle et al. 
identified a sequence encoding for what they called breast cancer resistant protein 
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(BCRP), which was overexpressed in the chemoresistant breast cancer cell line 
MCF-7/AdrVp, but not in its parental cell line MCF-7 or in its partially reverted MCF-
7/AdrVpPR subline (Doyle et al., 1998). 
3.3.2.1 ABCG2 EXPRESSION IN DIFFERENT TISSUES 
The ABCG2 drug transporter is expressed in many different organs like in the placen-
ta (Allikmets et al., 1998), brain, brain-blood barrier, prostate, liver, testis, ovary, 
small intestine and human embryonic stem cells (Apati et al., 2008) at different levels 
(reviewed by (Robey et al., 2007, Robey et al., 2009)). 
In human embryonic stem cells it could be shown that upon differentiation the cells 
lost ABCG2 expression (Apati et al., 2008). 
3.3.2.2 REGULATION OF ABCG2 EXPRESSION AND FUNCTION 
ABCG2 is expressed by the human ABCG2 gene located on chromosome 4q22 ex-
panding over 66 kb including 16 exons and 15 introns (Robey et al., 2007), (Robey et 
al., 2009). The translational start codon resides in exon 2. Exon 3 harbors the Walker 
A site. Its expression might be regulated at promoter level by sex hormones (Robey 
et al., 2007), its methylation status (Robey et al., 2007) and by hypoxia (Martin et al., 
2008). Indeed, under hypoxia, HIF-2 leads to increased ABCG2 expression, pro-
tecting the cells from oxidative stress (Martin et al., 2008) via increased efflux of its 
known substrate porphyrin which is induced upon hypoxia and which causes mito-
chondrial death (reviewed by (Krishnamurthy et al., 2004)). 
Mutation at Arg383 alters glycosylation of ABCG2 and retains it in the endoplasmic 
reticulum leading to proteasomal degradation and decreased ABCG2 protein level (Ni 
et al., 2010). Furthermore, some single nucleotide polymorphisms (SNPs) can reduce 
ABCG2 membrane expression decreasing efflux efficiency (Robey et al., 2007). 
Further, ABCG2 can be regulated at a functional level by inhibiting its insertion into 
the cell membrane, which is needed to fulfill its transport activity. Bleau et al. ob-
served that inhibition of the PI3K/Akt pathway resulted in decreased SP fraction in 
gliomas and ABCG2 translocated from the cell membrane into the cytoplasm (Bleau 
et al., 2009). Mogi et al. observed the same for bone marrow cells, where ABCG2 
expressed by sorted SP cells translocated from the cell membrane into the cytoplasm 
after PI3K/Akt pathway inhibition compared to untreated SP cells (Mogi et al., 2003). 
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An additional post-translational regulation of ABCG2 protein level and thus function is 
the formation of disulphide bonds in the extracellular loop of the protein structure (see 
below section 3.3.2.3). The formation of disulphide bonds is necessary for the stabil-
ity of ABCG2 (Wakabayashi et al., 2007). Disulphide bonds are formed in an oxida-
tive environment, which is found in the extracellular space. If the pH of incubation 
media drops (acidic environment), oxidative situation changes to a reductive envi-
ronment and by losing the disulphide bond, ABCG2 proteins get instable and thus 
degraded in an ubiquitin/proteasome dependent manner (Wakabayashi et al., 2007). 
3.3.2.3 PROTEIN STRUCTURE 
Since 1990 researchers are investigating the structure of ABC transporters. The dif-
ferent domains (ATP-binding domain, nucleotide-binding domain etc.) were already 
known by then, but only for about 30 by then identified ABC transporters (Hyde et al., 
1990). Additionally, they already observed substrate specificity of different subfami-
lies of the ABC transporters (Hyde et al., 1990). 
ABCG2 is built up by 665 amino acids leading to a protein of 72 kDa in size (Robey 
et al., 2009), (Velamakanni et al., 2007). Its transmembrane (TM) domain is located 
at its C-terminus (residues 361 – 655) and its ATP-binding domain (NBD) at its N-
terminus (Figure 10B). The TM domain provides the transporter’s substrate specificity 
(Velamakanni et al., 2007). The NBDs include three conserved sequences: Walker A 
and B motifs and the ABC signature motif giving its hallmark to each individual ABC 
transporter (Velamakanni et al., 2007). The transmembrane domain possibly harbors 
six TM (-helices) segments forming the pathway for the substrates to cross the lipid 
bilayer (Higgins and Linton, 2004). Between transmembrane segments five and six 
there is an extracellular loop (Robey et al., 2009) and it seems that ABCG2 includes 
three N-linked glycosylation sites (Robey et al., 2009). Alterations in specific residues 
of the extracellular loop may influence the oligomerization of the ABCG2 half-
transporter, its localization and therewith its function (Robey et al., 2009). 
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 Figure 10: ABCG2 schematic model (A). ABCG2 membrane topology (B). 
Adapted from Ni et al., 2010. 
 
3.3.2.4 OLIGOMERIZATION 
ABCG2 is expressed as a half-transporter, which has to oligomerize to get its full ac-
tivity. To investigate the oligomeric state of ABCG2, Xu et al. used a mild ionic deter-
gent leaving non-covalent interactions of protein subunits intact. With this method 
they observed that ABCG2 most likely occurs as homotetramer in living cells (Xu et 
al., 2004) not as homodimer as previously thought. Nevertheless, it is not known if 
the most abundant homotetramer is also the active form of ABCG2 or if it serves as a 
regulator for the level of functional ABCG2 where the homodimer would represent the 
active ABCG2 form (Xu et al., 2004). This means, if one oligomer forms, it decreases 
the level of the other and therewith decreases the active ABCG2 form in the cell 
membrane (Xu et al., 2004). McDevitt et al. investigated the 3D structure of ABCG2 
using electron microscopy and also claims that ABCG2 forms a tetramer of dimers 
(McDevitt et al., 2006). 
3.3.2.5 ATP HYDROLYSIS AND ITS EFFECT 
On the basis of substrate translocation across the cell membrane via ABC transporter 
is the ATP-switch model (reviewed by (Higgins and Linton, 2004) and illustrated in 
Figure 11). The initial step of the transport cycle is performed by substrate binding to 
its high-affinity site on the TM domain followed by increased affinity of NBDs for ATP 
(Higgins and Linton, 2004). This lowers the activation energy for ATP-dependent di-
merization (Higgins and Linton, 2004). Via binding of two ATPs to the NBDs, they 
undergo a conformational change resulting in the closed dimer (Higgins and Linton, 
B A 
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2004). This represents the power stroke upon which the TM domain undergoes a 
conformational change releasing its bound substrate into the extracellular space by 
reducing its binding affinity (Higgins and Linton, 2004). Next the ATPs get hydrolyzed 
leading to an intermediate transition-state in which the NBD closed dimer gets desta-
bilized (Higgins and Linton, 2004). This initiates the reset of the transporter into its 
basal configuration (Higgins and Linton, 2004). Therefore Pi and ADP are released 
successively restoring the transporters configuration to be ready for the next cycle 
(Higgins and Linton, 2004). 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: The ATP-switch model. Adapted from Higgins and 
Linton, 2004. 
 
3.3.2.6 ABCG2 SUBSTRATES AND INHIBITORS 
The association of ABCG2 to multidrug resistance in cancer cells led to the identifica-
tion of many ABCG2-specific chemotherapeutics. Well known chemotherapeutics 
effluxed via ABCG2 are, within others: mitoxantrone, topotecan, methotrexate, 
daunorubicin, doxorubicin, gefitinib and imatinib (reviewed by (Ni et al., 2010), 
(Robey et al., 2007)). Additionally, due to its expression in organs like the placenta or 
brain-blood barrier, it also effluxes non-chemotherapeutics like carcinogens (aflatoxin 
B1), antivirals, antibiotics and others like flavonoids (Vitamin P), riboflavin (vitamin 
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B2/E101) and vitamin K3 (reviewed by (Ni et al., 2010), (Robey et al., 2009)). Even 
though these substrates are well known to be transported by ABCG2, there is a re-
markable overlap of the substrate specificity between ABCG2 and MDR1. Neverthe-
less, MDR1 generally transports hydrophobic substrates whereas ABCG2 transports 
both hydrophobic as well as hydrophilic substrates (Ni et al., 2010). 
The first very specific ABCG2 inhibitor reported was fumitremorgin C (FTC) 
(Rabindran et al., 2000). Nevertheless, other inhibitors were reported earlier but the-
se were also inhibiting other ABC transporters like MDR1 and MRP1 (Robey et al., 
2009). 
Even though the list of substrates and inhibitors is large, no structure-function rela-
tionship could be identified so fare which could explain the requirements to be a sub-
strate or inhibitor for ABCG2 (Robey et al., 2009). 
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4 AIM OF THE THESIS 
As summarized above, patients diagnosed with malignant pleural mesothelioma 
(MPM) have a poor prognosis. Treatment is mostly palliative and patients mostly die 
within one year after diagnosis. Where chemotherapy is applied, patients develop 
resistance against chemotherapeutics. Therefore it is of great importance to improve 
mesothelioma treatment. 
For this purpose and according to the cancer stem cell model, the aim of this thesis 
was to identify cancer stem cells in malignant pleural mesothelioma and to character-
ize them in order to gain information about tumor recurrence after resection and the 
development of chemoresistance. 
Due to the lack of known mesothelial stem cells and its markers we used a more uni-
versal approach for the identification of potential cancer stem cells in malignant pleu-
ral mesothelioma. The side population assay is based on functional ABCG2 drug 
transporter expressed by cancer stem cells and able to efflux DNA dyes such as 
Hoechst 33342 or DCV. This assay was used to isolate SP cells of MPM which were 
then tested for their tumorigenic potential in NOD/SCID mice and further character-
ized concerning their self-renewal capacity, stem-like cell properties and their possi-
ble mesenchymal origin. In addition SP derived cells were tested for their chemo-
resistance. 
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Abstract  
 
DyeCycleViolet was used to set up the side population (SP) functional assay aimed 
at identifying subpopulations of malignant pleural mesothelioma (MPM) tumor cells 
with chemoresistance phenotype associated with ABCG2 transporter activity. Self-
renewal, chemoresistance and tumorigenicity were tested for SP and non-SP (NSP) 
cells. Tumors were characterized by mesothelin, calretinin, N-cadherin, D2-40 and 
Wilms tumor 1 (WT1) immunohistochemistry. Surface expression of mesenchymal 
stem cell markers CD90, CD73 and CD105 was investigated in SP and NSP cells. 
We identified SP cells with self-renewal properties and increased chemoresistance in 
MPM cell lines and tumor derived primary cell cultures. Compared to the non-SP 
fraction (NSP), the SP fraction led to the development of tumors including cells with 
mesothelium precursor phenotype characterised by mesenchymal morphology, being 
WT1 negative but cytoplasmic D2-40 positive, and having a tendency of increased 
tumorigenicity. The same phenotypic shift was observed in patients with relapsing 
tumors after chemotherapy. Furthermore the SP cells were enriched in CD105 -/low 
expressing cells which were small sized and had increased tumorigenicity compared 
to CD105 high cells. Taken together our results support the hypothesis that MPM 
CD105-/low, chemoresistant, small sized SP cells may constitute the cellular pool out 
of which recurrence develops. Further characterization of mechanisms of 
chemoresistance and self-renewal should lead to targets specific for this 
subpopulation in MPM patients. 
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Introduction 
Asbestos-related malignant pleural mesothelioma (MPM) is expected to peak in 2020 
[1]. Survival rate are still around one year (depending on the age and treatment) after 
diagnosis [2]. Objective chemotherapy response is achieved in less than 50% of 
patients and has limited duration [3]. 
In order to gather a better understanding of MPM biology which may ultimately help 
defining better therapeutic strategies we considered parallel aspects between MPM 
development and other tumors linked to chronic injury [4]. The asbestos fibres-
induced MPM development is due to accumulation of inhaled asbestos fibres in the 
pleural space and subsequent damage of the mesothelium [5]. Chronic tissue repair 
follows, activating stem cell signalling pathways to regenerate the tissue but, 
because of persistent system stimulation, oncogenic events occur leading to tumor 
formation (reviewed in [6]). The presence within the latter of a population of cancer 
stem cells (CSC) highly resistant to chemotherapy might be the cause of tumor 
recurrence. Hence, the aim of our study was originally to identify and characterize 
MPM CSC. The latter, which have the capability to create exact tumor phenocopies 
when transplanted from one mice to the next, have been proposed to exist [7] based 
on the pioneer work identifying leukemic stem cells as CD34+/CD38- cells, like 
hematopoietic stem cells (HSC), in human acute myeloid leukemia (AML) [8], [9]. The 
presence of CSCs in solid tumors was identified for the first time as a small subset of 
heterogeneous breast cancer cells which were phenotypically distinct and 
characterized as CD44+/CD24-/low [10]. Since then, for many solid tumors cancer 
stem cells have been identified using corresponding tissue stem cell surface markers 
(reviewed in [11]). Normal mesothelium stem cell surface markers are not yet 
available to identify potential MPM CSCs. Hence, we used a functional assay which 
identifies a small and distinct subset of cells, called “side population” (SP), with 
phenotypic markers of multipotential HSC after staining bone marrow with the DNA 
staining dye Hoechst 33342 [12]. The SP is due to the expression of functional ATP-
binding cassette (ABC) transporters [13]. When living cells are stained with Hoechst 
33342, SP cells do efflux the DNA staining dye via their ABC transporters. When 
cells are co-incubated with ABC transporter inhibitors verapamil or fumitremorgin C 
(FTC), Hoechst 33342 is no longer effluxed leading to a shift in the dual emission 
wavelength fluorescence activated cell sorting (FACS) analysis upon which the SP 
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can be identified. The ABCG2 drug transporter is responsible for the SP in the bone 
marrow [13], [14]. Although this assay has already been applied to mesothelioma cell 
lines [15] several issues are still needed to be addressed. First, self-renewal of sorted 
SP has not been investigated yet, second tumorigeniciy has been determined only 
for SP and NSP cells sorted from MS-1 cell line, which has a biphasic histotype and 
no differences were found. In our study, those questions were addressed using 
primary cultures from xenografts, either from a cell line or from a patient derived 
tumor instead of cell lines. In addition, surface phenotype and chemoresistance were 
characterized.  
 
 
Material and Methods 
 
Tissue samples 
Human tumor specimens were obtained and processed as previously described [16], 
[17]. 
 
Cell lines and primary cell cultures 
The human promyelocytic leukemia cell line HL60/Dox selected by chronic exposure 
to doxorubicin was kindly provided by Dr. M. Andreev (Department of Blood and 
Marrow Transplantation, UT MD Anderson Cancer Center, Huston, Texas) and 
maintained in RPMI 1640 (Sigma – Aldrich) supplemented with 10% FCS (Omnilab), 
1% penicillin/streptomycin and 1mM L-Glutamine (both obtained from GIBCO). The 
breast cancer cell line MCF-7 was maintained in RPMI 1640 supplemented with 10% 
FCS, 1% penicillin/streptomycin and 2mM L-Glutamine. Primary MPM cell cultures 
were established from surgical specimens or xenografts as follows: tumors were 
blended into small pieces of 1 to 3 mm2, then fragments were directly added to 
culture medium adapted from Connell et al. [18] (DMEM/F12+GlutaMax (GIBCO), 
15% FCS, 0.4 g/ml hydrocortisone (Sigma – Aldrich), 10 ng/ml EGF (epidermal 
growth factor, GIBCO), 1% ITS (insuline, transferrin, selenium, GIBCO), 1 mM 
sodium pyruvate (Sigma – Aldrich), 100 M beta-mercaptoethanol (Fluka), 
supplemented with 1% non-essential amino acids (GIBCO) and 30% conditioned 
medium), or were incubated with collagenase 3 (200 U/ml, Worthington Biochemical 
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Corporation, New Jersey, USA) and hyaluronidase (100 U/ml) for 6h at 37 C followed 
by digestion with 0.25% Trypsin/EDTA (ethylenediaminetetraacetic acid, GIBCO) for 
2 min at 37°C and with 20 mg/ml DNAseI (Worthington Biochemical Corporation, 
New Jersey, USA) for additional 2 min at 37°C. At the end of the collagenase 
digestion, tissues were filtered through a 70 µm cell sieve. The filtrate was 
centrifuged and the pellet resuspended in culture medium. The mesothelioma cell 
lines ZL34 and ZL55 were established in our laboratory [19]. The MPM cell line H28 
and Met5A, a mesothelial cell line obtained by SV40 transformation of mesothelial 
cells [20], were obtained from ATCC. All cell lines used in this study were 
authenticated by DNA fingerprinting (Microsynth, Switzerland). 
 
Gene expression analysis 
Selected gene expression analysis was performed as previously described [16], [17] . 
Additional primers are listed in the Supplementary Table I. The heatmap was 
produced with R using default options on ∆Ct raw data. We used the logarithmic 
expression values and subtracted for each gene its mean expression. 
 
Measurement of cell growth 
To test sensitivity to mitoxantrone, cells were first incubated for 1 h with mitoxantrone 
(Sigma – Aldrich) (1 ng/ml) then verapamil (20 M) was added or not for 1 h. Both 
drugs were suspended in medium without serum. After incubation, drugs were 
removed and cells were grown for further 3 days in serum containing medium. 
Sensitivity to cisplatin (0 – 16 M) was tested in MPM medium containing 0.5% FCS. 
Cell growth was determined as previously described [21]. 
 
Western blot analysis 
Western blotting was done as described [16]. The Western blots are representatives 
of 2 – 5 independent experiments. 
 
Side population analysis 
Cells were stained with DCV using a previously described method [22], [23], [24] and 
adapted as follows. Briefly, cells were washed with PBS, trypsinized and 
resuspended in DMEM:F12 supplemented with 2% FCS, 10 mM 4-(2-hydroxyethyl)-
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1-piperazineethanesulfonic acid (HEPES, Sigma – Aldrich), 0.4 g/ml hydrocortisone, 
10 ng/ml EGF, 1% ITS, 100 M -mercaptoethanol, 1 mM sodium pyruvate, 2 mM L-
Glutamin and 1% non-essential amino acids. As positive controls, HL60/Dox cells 
were used. Cells were incubated with DCV (0.5 M, Invitrogen) in the absence or 
presence of verapamil (50 M; Sigma – Aldrich) at 37°C for 90 min in the dark mixing 
every 15 min. Then cells were spun down at 4°C and resuspended in ice-cold Hanks’ 
balanced salt solution (HBSS, GIBCO) supplemented with 10 mM HEPES and 5 mM 
EDTA (Amresco). Viable cells were gated with propidium iodide (PI, 2 g/ml). Cells 
were gated on the FACSAria (Becton Dickinson) FSC and SSC, a live gate was 
placed on cells excluding PI (Ex 488 nm, Em 610/20 nm) and single cells were gated 
based on FSC (FSC lin vs pulse width) and SSC (SSC lin vs pulse width). SP was 
determined by a gate placed on 450/40 vs 530/30 nm emission dot plot on a 
logarithmic amplified fluorescence scale after DCV excitation at 407 nm [25]. The SP 
gate was identified using verapamil which blocks drug efflux. These settings gave the 
same results as 450/40 vs 650 nm longpass and allowed a direct comparison with 
results on surface phenotyping using the CyAn ADP analyzer (Beckman Coulter), 
described below where only the 530/40 nm filter for 405 nm excitation was available. 
After sorting cells were cultured or processed for mice xenografts. 
 
Immunohistochemistry 
De-paraffinized sections were subjected to antigen retrieval using Tris/EDTA (1 
mM/0.1 mM, pH9) or pepsin digestion (for WT1). Following quenching in 0.3% H2O2 
(20 min) and permeabilization in 0.05% Saponin (Fluka, 5 min), blocking was 
performed in 2% bovine serum albumin (BSA) in PBS with 1% horse serum (Vector 
Laboratories, 20 min) at room temperature. Sections were incubated with primary 
antibodies (in supplementary figures: N-cadherin 6G11, 1:50; DAKOCytomation, 
mesothelin 5B2, 1:30; NovoCastraTM Laboratories, calretinin 1:50, Abcam) overnight 
at 4°C. Negative controls were incubated with secondary biotinylated antibody only 
(Vectastain® Elite® ABC Kit, Vector Laboratories). Sections were washed with PBS 
and incubated with secondary biotinylated antibody for 45 min at room temperature. 
Staining was visualized using 3,3’-diaminobenzidine tetrahydrochloride (Sigma – 
Aldrich), counterstained with Vector® Hematoxilyn QS (Vector Laboratories) and 
analysed either using a Leica DM IRBE microscope and image acquisition with Nikon 
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Coolpix and Retiga Cooled Color 12-bit camera and QCapture (QImaging) or using a 
Zeiss Mirax Midi Slide Scanner and image acquisition with a 3CCD colour camera 
and Mirax Viewer (Zeiss). A minimum of 200 cells was evaluated. 
 
Surface phenotyping 
Cells resuspended in ice-cold PBS/2mM EDTA were incubated with antibodies 
against CD105 (SN6, APC-labelled, eBioscience), CD90 and CD73 (5E10 and AD2, 
respectively, both phycoerythrin (PE)-labelled, BD Bioscience) and podoplanin 
(purified, kindly provided by Dr. D. Kerjaschki, Clinical Institute for Pathology, Medical 
University of Vienna, Vienna, Austria) and with allophycocyanin (APC)-labelled, PE-
labelled and purified IgG controls (eBioscience and BD Bioscience, respectively) at 
4°C for 30 min in the dark. Secondary antibody (PE-labelled, Dianova) for podoplanin 
analysis was incubated at 4°C for 30 min in the dark. After washing with PBS cells 
were resuspended in ice-cold PBS/2mM EDTA and analyzed. CD105-/low and 
CD105high cells were identified and electronically gated on either the FACSAria cell 
sorter or the CyAn ADP analyzer (Beckman Coulter) after APC excitation at 633 nm. 
The purity of sorted cells was verified directly after sorting and was >98%. 
Where additionally SP was investigated, cells were treated for the SP analysis prior 
to antibody incubation. 
The expression of ABCG2 on the cell surface was verified by FACS analysis as 
described [26]. 
 
MPM xenografts into NOD/SCID mice 
NOD/SCID mice were bred and maintained under conditions approved by the Animal 
Care Committee. Sorted cells were resuspended in Matrigel (Matrigel Basement 
Membrane Matrix; Becton Dickinson) and injected under the renal capsula of 6 - 8 
weeks old mice that were irradiated with 1 Gray one day before injection [27]. Tumor 
tissues obtained from patients were directly implanted under the renal capsula. The 
mice were anesthetized with isoflurane while cells were injected. All animals were 
sacrificed between 13 and 21 weeks post-transplantation. Tumor volume in cm3 was 
determined using the formula (length x width2) / 2, where length was the longest axis 
and width being the measurement at right angles to the length. 
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Results 
 
Identification and characterization of a side population in the MPM cell line 
ZL55 
In preliminary experiments we established a side population protocol using as an 
experimental control [28] the leukemia cell line HL60/Dox, which over expresses 
multidrug resistance proteins allowing the cells to efflux the DNA staining dyes 
Hoechst 33342 or DyeCycleViolet (DCV). We observed that using DCV, which has 
the advantage of being excited at non-UV wavelength with an enhanced emission 
signal compared to Hoechst 33342 [23], resulted in a better separation of SP/NSP 
(Supplementary Figure 1A). In addition we found that DCV could be used at a 
concentration (0.5 M) not toxic to cells (Supplementary Figure 2), allowing to take 
into account cytotoxicity concerns about this method [29]. This DCV protocol was first 
applied to breast cancer cell line MCF-7 [30] to provide an additional control for low 
abundance SP (Supplementary Figure 1B and Table I). 
Using the DCV protocol for the MPM cell line ZL55 (gating strategy presented in 
Supplementary Figure 3), we identified a SP of 2.1 ± 1.9 % (n = 31, mean±SD, 
Figure 1A and Table I), which was decreased by the drug transporter inhibitor 
verapamil, indicating that these cells represented the SP cells. To examine whether 
SP cells could regenerate SP and NSP cells, ZL55 cells were sorted into SP and 
NSP and further cultured in vitro. Reanalysis of ZL55 SP and NSP in respect to their 
SP/NSP distribution revealed that ZL55 SP was able to regenerate a SP (2.25 %, n = 
2), whereas only NSP (n = 2) was obtained with ZL55 NSP. These data suggest that 
a SP with self-renewal properties is present in MPM ZL55 cells. In addition the ZL55 
SP was enriched with cells expressing the drug transporter ABCG2 at both protein 
and mRNA level (Figure 1B). To further characterize SP vs NSP derived populations 
the expression of N-cadherin and mesothelin, which we routinely use to characterize 
our primary cultures [16], were investigated. Both N-cadherin and mesothelin (Figure 
1C, left panel) were not detected in ZL55 SP cells in which a higher relative 
expression of Sox2 was observed (data not shown). This might indicate that ZL55 SP 
cells are in a less differentiated state. The relative expression of MDR1 was also 
increased in the SP fraction (Figure 1D), which is not surprising given the fact that 
DCV is a substrate of various ABC transporters. Relative expression enrichment was 
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also observed for ABCC3 but not for ABCC1. All in all, these data indicate that a SP 
with stem/progenitor cell properties is present in ZL55 cells. 
 
Characterization of SP in additional MPM cell lines, MPM primary cell cultures 
and in a primary mesothelial cell culture 
Beside the mesothelioma cell line ZL55 we investigated the SP distribution in 2 
additional MPM cell lines ZL34 and H28, in 3 primary MPM cell cultures SDM96, 
SDM100 and SDM138, in a xenograft derived primary MPM cell culture SDM103T2 
(Figure 1A) and in a primary mesothelial cell culture SDM104. In all these cell lines 
and primary cell cultures a SP was identified (Table I).  
The fact that a SP is also present in the primary mesothelial cell culture SDM104 
indicates that a fraction of cells with potential self-renewal capacity is present in 
cultured normal mesothelium. 
SDM103T2 cells were selected for further characterization for two reasons: first, they 
were derived from xenograft implantation of a tumor after chemotherapy, offering the 
opportunity to detect chemotherapy resistant cells. Second, tissue of relapsed tumor 
from the same patient was also available for further comparison. As for ZL55 cells, 
the SDM103T2 SP (Figure 1B, right panel) showed increased expression of ABCG2 
and was able to regenerate a next SP (2.25 %, n = 1) when cultured. The latter 
(SDM103T2 SP1 SP1, Figure 1B) was even further enriched for ABCG2 expression 
compared to the remaining NSP (SDM103T2 SP1 NSP1). Similarly to ZL55 cells, the 
expression of the MPM marker mesothelin was lower in SP compared to NSP (Figure 
1C, right panel) while this trend was not observed for N-cadherin. Thus, it seems that 
SP phenotype is accompanied by decreased expression of mesothelin, which is 
generally abundantly expressed in epithelioid MPM [31]. No specific enrichment of 
other ABC transporters in the SP fraction was observed (data not shown). 
 
SP cells tend to be more tumorigenic than NSP cells 
To test whether the tumorigenicity of SP and NSP differs, various numbers (102 -105) 
of sorted ZL55 cells were injected under the renal capsule of NOD/SCID mice and 
monitored for tumor development. Both ZL55 SP and NSP gave rise to tumors when 
105 cells were implanted (n=4). By decreasing the injected cell number below 103, 
neither ZL55 SP nor NSP gave rise to tumors (n=2). Injecting between 103 and 104 
cells of ZL55 SP and NSP led to tumor development for both SP and NSP in three of 
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four mice tested. Therefore, similar to another study [15] no difference in a cell line 
SP vs NSP tumorigenicity was observed. We then injected sorted SP and NSP cells 
derived from a SP (ZL55 SPT) and a NSP (ZL55 NSPT3-3) tumor. Both cell cultures 
gave rise to a SP fraction (0.9 ± 0.7 % and 0.2 ± 0.1%, n = 8 and n = 3, respectively). 
By injecting between 103 and 104 of these tumors’ derived, sorted cells, there was a 
tendency (Figure 2A) to observe tumor formation more frequently with the SP 
fraction. For the xenografted tumor derived SDM103T2 only SP cells gave rise to 
tumors. All in all, there is a tendency (p=0.12, two-tailed chi-square test) for the SP 
fraction to have higher tumor initiating ability (8/14) compared to NSP fraction (4/14).  
The existence of intrinsic differences between SP and NSP sorted cells was 
supported by colony forming efficiency (CFE) assay. Plating ZL55 SPT SP and NSP 
cells resulted in the growth of two colony-types: compact and loose (Supplementary 
Figure 4). The yield of loose colonies was significantly (p<0.01, Mann-Whitney test) 
higher in ZL55 SPT NSP compared to SP. SDM103T2 could not be analyzed in a 
similar way because cells grow spreading in the dish. However, a similar observation 
was obtained in ZL34 cells. 
 
SP derived tumors shift their expression toward mesothelium precursor 
phenotype 
In order to get further insight into the mechanism of increased tumorigenic potential 
of SP derived cells, gene expression and immunostaining was performed on SP and 
NSP derived tumors. The relative expression of mesothelioma markers calretinin 
[32], podoplanin [33 ] and mesothelin [31]; ABC transporters ABCG2, MDR1 and 
ABCC1; stem cell markers Sox2, nestin, OCT4A, Bmi-1, CD90; sonic hedgehog 
activity markers Gli-1, Patch1; hypoxia controlled CAIX and Wisp2 and matrix 
remodeling Slug, Twist and PAI-1 were investigated in ten ZL55 SP and NSP derived 
tumors. Some mouse genes (Gli-1, Patch1 and Sca-1) were also included to take 
into account mouse stromal components. Although of all the genes analyzed only 
Patch-1 was significantly enriched in SP derived tumors (p<0.05, two way ANOVA), it 
nevertheless indicates that SP and NSP derived tumors are different and suggests 
the involvement of sonic hedgehog signalling. An unsupervised clustering showed 
separation of SP and NSP tumors (Figure 2B) with the exception of three tumors. In 
addition to Patch1, the expression of podoplanin was enriched in SP compared to 
NSP derived tumors. Latter observation was confirmed by immunostaining of tumor 
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sections (Figure 2C, 2D and Table II) where we observed that podoplanin staining 
shifted from the membrane to the cytoplasm in SP derived tumors. It is noteworthy 
that podoplanin, also called D2-40 antigen, is a marker of splanchnic mesoderm [34] 
from where mesothelium derives. Hence, SP derived tumors have an increased 
expression of mesothelium precursor marker. 
Mesothelioma is classified according to histopathology into epithelioid, biphasic and 
sarcomatoid subtype, with the biphasic type being defined as a tumor comprising 
more than 10% of both epithelioid and sarcomatoid areas [35]. In SP derived tumors 
we observed a morphological shift from 100% epithelioid tumor to a mixed 
morphology for ZL55 derived tumors or to an increased spindeloid phenotype for 
SDM103T2 cells (Table II). The latter was paralleled by a significant decrease 
(p<0.01) in cells with positive nuclear WT1 immunostaining (30% and 98% in ZL55 
and SDM103T2 derived tumors, respectively). WT1 is a transcription factor 
expressed at the time of switch from mesenchymal to epithelial cells (MET) in 
mesothelium precursor cells [36]. Continuous WT1 expression is conserved in 
mesothelium through adult life and is maintained in mesothelioma [37]. However, it 
decreases during epithelial to mesenchymal transition (EMT) occurring for example 
in sarcomatoid mesothelioma [38]. Altogether these data indicate that SP derived 
tumors shift their expression toward mesothelium precursor phenotype. 
In contrast to observations in vitro where differences in mesothelin and N-cadherin 
expression were observed in SP and NSP fractions, all tumoral cells showed positive 
immunostaining for these markers (Supplementary Figure 5). There can be many 
reasons for it, including growth in an in vivo environment. In addition, all tumors were 
positive for calretinin. 
The resistance of stem-like cells to conventional chemotherapy is thought to be the 
cause of tumor recurrence. Hence, we investigated whether the recurrence tumor 
SDM141 from the patient SDM103, from which SDM103T2 were derived, would have 
a similar shift toward mesothelium precursor phenotype, defined here as the absence 
of WT1 expression, podoplanin shift from membrane to the cytosol and spindeloid 
phenotype. We observed indeed a loss of WT1 expression, an increased cytosolic 
podoplanin immunostaining and a shift toward sarcomatoid morphology in SDM141 
sample compared to epithelioid SDM103 phenotype (Figure 2E). These observations 
indicate first that in the xenograft (SDM103T2) grown in mice, cells selected to grow 
were already shifting to spindeloid phenotype compared to parental tumor and 
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second that xenografted SP cells behave like relapsing tumors, buttressing the 
hypothesis that relapse might be due to resistant cancer stem-like cells. Similar 
results were observed for tumor evolution in other two patients (Supplementary 
Figure 6). 
 
ZL55 SPT cells were more chemoresistant to chemotherapeutics 
Since mesothelioma patients develop resistance against chemotherapy and because 
ABCG2 expression is correlated with a higher resistance to chemotherapeutics, we 
investigated the chemoresistance of ZL55 SPT and ZL55 NSPT3-3 cells. The latter 
were incubated either with verapamil, with mitoxantrone, a known ABCG2 substrate, 
or with a combination of verapamil and mitoxantrone (Figure 3A). ZL55 SPT cells 
were more resistant to mitoxantrone compared to ZL55 NSPT3-3 cells, but this 
difference was abolished (p<0.01, paired t test) in the presence of verapamil. 
Additionally, ZL55 SPT and ZL55 NSPT3-3 cells were incubated with different 
concentrations of cisplatin, a chemotherapeutic agent commonly used for the 
treatment of mesothelioma patients. Also in this case, ZL55 SPT cells were 
significantly (p<0.001, t-test) more resistant to a high concentration of cisplatin 
compared to ZL55 NSPT3-3 cells (Figure 3B). Cisplatin induced DNA damage was 
similar in both ZL55 SPT and NSPT3-3 cells as indicated by the phosphorylation of 
the histone variant H2AX (Figure 3C), occurring downstream DNA damage response 
(DDR) (reviewed in [39]). However, a better survival in ZL55 SPT compared to 
NSPT3-3 cells was correlated with higher basal expression of survivin (Figure 3C), 
an antiapototic protein upregulated in MPM [40]. In addition, cisplatin exposure 
resulted in a further increase of survivin levels which contributes to chemoresistance, 
as we have previously described [41]. All in all, these data indicate that SP derived 
cells are more chemoresistant. 
 
SP cells are CD105-/low 
To gather more information on the SP phenotype we determined whether 
mesenchymal stem cell markers CD105, CD90 and CD73, which were expressed in 
all MPM investigated (Supplementary Table II), would be differentially expressed in 
the SP itself. We also investigated the expression of podoplanin and of ABCG2, 
which were differentially expressed in the various cultures. The SP was specifically 
enriched in CD105-/low cells for SDM103T2 (4.9 ± 2.8 fold enrichment, n = 4) (Figure 
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4A). Similar results were obtained for ZL55 cells. In addition CD105-/low cells were 
smaller (Figure 4B). No specific enrichment was observed with the other two 
markers. Sorted ZL55 CD105-/low cells induced tumors which were five times larger 
(p<0.02, n = 4, t-test) compared to CD105high cells buttressing the existence of a cell 
subpopulation with high tumorigenic potential (Figure 4C). Consistent with this 
observation, Ki67 proliferation marker immunostaining was more abundant in ZL55 
CD105-/low cells (Figure 4D). 
 
 
Discussion 
In this study we identified a SP with self-renewal and chemoresistance capacity, 
enriched in CD105-/low cells and able to induce, when implanted under the renal 
capsule of NOD/SCID mice, the growth of a tumor with increased spindeloid 
morphology. Furthermore, we observed that CD105-/low cells develop larger tumors 
compared to CD105high cells. Unfortunately the yield of SP in CD105-/low cells was 
insufficient to allow any investigation of the double selection. However, based on 
current knowledge on embryonic mesothelium development, the proposed 
recruitment of adult precursor cells by asbestos [42] and on our own results we put 
forward the hypothesis that MPM SP CD105-/low cells include mesothelioma cells 
responsible for tumor recurrence in patients (Supplementary Figure 7). 
MPM SP fractions varied between cell cultures but were in the same range of 
magnitude as found in other cancer types [43]. They were enriched for ABCG2 
transporter expression as observed by others [44], [28] and the fraction of ABCG2 
surface positive cells was in a similar range as the SP fraction. In addition the 
ABCG2 specific inhibitor FTC [45] inhibited dye efflux (data not shown), therefore it is 
likely that ABCG2 is responsible for the SP phenotype in MPM. 
The epithelioid differentiation marker mesothelin was low in the SP fraction. Not 
much is known about the regulation of mesothelin expression. However in MexTag 
mice in which the SV40 T-antigen (Tag) is under the control of the mesothelin 
promoter and which develop MPM tumors upon exposure to asbestos fibres, Tag is 
not detected in the unexposed mice [46]. This may indicate that the cells that are 
stimulated to proliferate upon asbestos fibres exposure are undifferentiated precursor 
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cells. The latter have been recently described in normal mesothelial primary cultures 
[47]. 
Similar to another study using MS-1 MPM cell line [15] no difference in tumorigenicity 
of SP vs NSP was observed, when starting material was a cell line. Nevertheless 
tumors from xenograft derived SP had a tendency to be more frequent, but most 
importantly shifted toward a precursor phenotype defined here as enriched for 
podoplanin expression and low WT1 expression. Consistent with an MET 
(mesenchymal-epithelial transition) concept and precursors being of mesenchymal 
phenotype, SP derived tumors shifted backwards from epithelioid to spindeloid 
morphology characterized by cytoplasmic podoplanin expression as observed by 
others [33], [48], [49, 50] and decrease of nuclear WT1 staining [38]. This phenotype 
shift cannot be attributed to the microenvironment, since such changes were not 
observed in NSP cells derived tumors developed contra laterally. In addition the 
increase in mesenchymal profile was consistent with the hypothesis that 
mesothelium injury, due to asbestos fibres accumulation in the pleural space, 
activates tissue repair involving mesenchymal stem cells (MSC) [42]. It is possible, as 
suggested by Beachy et al.[4], that persistent injury and stimulation of repair would 
lead in such cells to oncogenic events, represented in our model by the loss of NF2 
and INK4A function (reviewed in [51]. 
Further, we investigated MSC markers CD105, CD90 and CD73 expression in MPM 
cell lines and primary cell cultures. All investigated MPM cell lines and primary cell 
cultures were positive for all three MSC markers but only CD105 was differently 
expressed in SP and NSP: SP was enriched in CD105-/low cells. The latter developed 
larger tumors compared to CD105high cells. CD105 is an ancillary transforming growth 
factor  receptor, and it is not clear whether its differential expression in MPM cells is 
responsible for the observed phenotype. In hematopoietic stem cells CD105 positive 
cells contain all the long term repopulating HSC activity within bone marrow SP [52] 
while others have suggested a function of CD105 as a tumor suppressor in epithelial 
cancer [53]. Hence, functional studies are necessary to address any role of CD105 in 
MPM tumorigenicity. Intriguingly CD105-/low cells had also a smaller size. This is in 
line with observation from Grichnik et al. who identified SP cells in metastatic 
melanoma cell lines which, compared to NSP cells, were small in size and gave rise 
to a heterogeneous cell population [54]. A small size for stem-like cells has also been 
reported in glioma cells [30] and in squamous cell carcinoma (A431) cells [55]. 
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Alternatively to the hypothesis that asbestos fibres recruit and alter a mesothelium 
precursor, acquisition of oncogenic lesions may occur in terminally differentiated cells 
resulting in dedifferentiation to a primitive stem-like state. This state is often 
associated with epithelial to mesenchymal transition and chemoresistance [56] like 
observed in our study. It would be interesting to further investigate the potential of 
induction of differentiation as therapeutic option. In this context it is noteworthy that 
all-trans-retinoic acid treatment decreased growth of a sarcomatoid malignant pleural 
mesothelioma cell line in vivo without induction of apoptosis [57]. Since WT1 is 
controlled by retinoic acid [58] one possibility which remains unexplored, is that WT1 
was induced and it led to tumor cell differentiation and growth arrest.  
Taken together our results support the hypothesis that MPM recurrence develops 
from mesothelium-precursor-like cells. But most importantly we rise for the first time 
an issue that is seldom taken into account in mesothelioma biology: mesothelium has 
mesodermal origin and undergoes mesenchymal to epithelial transition during 
development. Mesothelioma progression, from epithelioid to biphasic to sarcomatoid 
seems to follow a "backward to precursor" epithelial to mesenchymal transition, 
which for the moment has not been thoroughly addressed because of the complexity 
of mesothelium itself which maintains some mesenchymal characteristics (e.g. 
vimentin expression). Using tools that are already largely used in the clinic such as 
immunohistochemistry for WT1 and podoplanin we provide knowledge that could be 
easily implemented in large cohorts of patients to verify whether it could predict time 
to relapse and allow adaptation of patient follow-up. 
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Tables 
Table I  - Average SP abundance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NA = not applicable; MPM = mesothelioma; SP = side population; * Used as 
control [28]. 
 
 
 
Cell line  Average  
SP (%) 
number of 
replicates 
Breast cancer* MCF-7 2.3±0.5 5 
    
MPM ZL55 2.1±1.9 31 
 ZL34 0.4±0.1 3 
 H28 0.7±0.3 4 
Primary MPM SDM96 1.1 2 
 SDM100 1.1 2 
 SDM103T2 1.6±1.5 24 
 SDM138 0.2±0.2 3 
Primary 
mesothelial 
cells SDM104 2.8 2 
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Table II  - Spindeloid cells and higher cytoplasmic podoplanin expression in 
ZL55 SP and SDM103T2 SP derived tumors compared to contra laterally 
derived NSP tumors or parental cells 
 Morphology Podoplanin 
 
Epithelioid Spindeloid 
% positive 
cells 
Mb Cyt 
Mouse 1      
ZL55 SPT3-3 90% 5-10% 5 + ++ 
ZL55 NSPT3-3 100% 0% 2-5 ++ + 
Mouse 2      
ZL55 SPT SPT2 95% 5% 30 ++ ++ 
ZL55 SPT NSPT 100% 0% 10 ++ + 
Mouse 3      
ZL55 SPT SPT3 95% 5% 80 + ++ 
ZL55 SPT NSPT2 100% 0% 30-40 ++ + 
      
SDM103T2 20 80 50 ++ + 
SDM103T2 SPT 10 90 10 + +++ 
SDM103T2 SPT2 0 100 50 + +++ 
 
SPT, side population derived tumor; NSPT, non-side population derived tumor; Mb, 
membrane; Cyt, cytoplasmic. 
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Figures 
Figure 1. 
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Figure 1 - ABCG2 and mesothelioma markers expression in the side population 
of a MPM cell line and a primary MPM xenograft cell culture 
(A) MPM cell line ZL55 and xenograft SDM103T2 cells were stained with DCV       
(0.5 M) in the absence (–) or presence (+) of verapamil (50 M). The side 
population (SP, green gate) was defined as the population decreasing by the addition 
of verapamil. (B) Western blot and real-time PCR analysis to assess ABCG2 
expression levels in sorted SP and non-SP (NSP) cells. ABCG2 protein (BXP-21, 
1:1000, Alexis, Biochemicals) was elevated in both ZL55 and SDM103T2 SP cells 
compared to NSP and parental cells. ABCG2 mRNA was also enriched in ZL55 SP 
cells. (C) Western blot analysis to determine the expression of mesothelin (MN-1, 
1:1000, Rockland Inc.) and N-cadherin (32/N, 1:2500, BD Bioscience) mesothelioma 
markers. Met5A cells were used as positive control for these two mesothelioma 
differentiation markers. Mesothelin was decreased in exponentially growing sorted 
SP cells. N-cadherin was also decreased but only in ZL55 SP cells. (D) Real-time 
PCR analysis revealed higher MDR1 and ABCC3 mRNA expression in ZL55 SP 
compared to NSP cells. Real-time PCR data were normalized to histones and 
expressed as mean ± s.d. (n = 3). Actin (C4, 1:10’000, ICN) was used as western 
blot loading control. 
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Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Different phenotypes in freshly sorted SP/NSP and their derived 
tumors 
(A) SP from xenograft derived tumors were enriched for tumor forming capacity in 
NOD/SCID mice. 103 - 104 cells were implanted under the renal capsula of 1 Gy 
C 
B A 
D E 
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irradiated mice. (B) Unsupervised clustering of SP and NSP derived tumors. 
Analyzed genes include ABC transporters ABCG2, MDR1 and ABCC1; stem cell 
markers Sox2, nestin, OCT4A, Bmi-1, CD90; sonic hedgehog activity markers Gli-1, 
Patch1; hypoxia controlled CAIX and Wisp2 and matrix remodelling Slug, Twist and 
PAI-1. Matrix of relative gene expression values is shown as heatmap. Red indicates 
down-regulated genes, blue indicates up-regulated genes. (C, D) Representative 
tumors stained with either hematoxylin and eosin (H & E), without primary antibody 
(control) or with antibodies against WT1 (6F-H2, 1:50, DAKO Cytomation) or 
podoplanin (D2-40, 1:50, DAKO Cytomation). WT1 expression decreased in SP 
derived tumor tissues while podoplanin shifted from the membrane to the cytosol 
compared to NSP derived tumor tissues for ZL55 cells and SDM103T2 tumor. (E) 
Tumor relapsing in patient SDM103 shifts toward mesothelium precursor phenotype, 
defined as the absence of WT1 expression, increased podoplanin cytosolic staining 
and spindeloid phenotype. 
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Figure 3.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C) Western blot analysis to assess the expression of the DNA damage sensing 
protein H2AX biomarker (JBW301, 1:1000, Millipore upper panel) and the survival 
protein survivin (Pab, 1:1000, R&D Systems, lower panel). No difference in the 
H2AX biomarker expression between the two lines was detected, however ZL55 
SPT cells showed increased survivin expression. 
 
 
A 
B 
C 
Figure 3 - SP derived tumor 
cells are more chemore-
sistant  
(A, B) ZL55 SPT and NSPT3-3 
cells were plated in 96-well 
plates and treated 24h later 
with verapamil (50 M), 
mitoxantrone (1 ng/ml), and a 
combination of the two for 1h, 
or with different cisplatin 
concentrations for 72h. The 
MTT assay was performed 
72h after beginning of the drug 
treatment. ZL55 SPT derived 
cells were more (*, p<0.01) 
chemoresistant to mitoxant-
rone compared to NSPT3-3 
derived cells and this 
difference was abolished by 
verapamil. ZL55 SPT cells 
were also more (*, p<0.001) 
resistant against high doses of 
cisplatin. The data were 
normalized to the drug-
untreated control. 
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Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 - SP cells are enriched in CD105-/low cells with increased 
tumorigenicity 
(A) The DCV efflux assay was performed to identify SP cells as indicated in the 
legend to Figure 1, followed by cell staining with an antibody against CD105 labelled 
with APC (SN6) to identify CD105-/low and high expressing cells. The SP fraction was 
then evaluated gating these two populations. (B) SDM103T2 cells were stained with 
anti-podoplanin and anti-CD105, then CD105-/low and high cells were analysed in a 
FSC Area histogram (cell size, lower panel) revealing that CD105-/low cells (blue) are 
smaller in cell size compared to CD105high cells (red). Number above the cell size plot 
represents the cell size ratio of CD105-/low to CD105high cells size (n = 9). (C) CD105-
/low and high expressing ZL55 cells were sorted, mixed with Matrigel and injected 
under the renal capsula of 1 Gy irradiated NOD/SCID mice. Tumor volume was 
assessed after 12 weeks. CD105-/low cells induced significantly (*, p<0.02) bigger 
A B 
C D 
63 
 
tumors. (D) Increased proliferation in representative CD105-/low and high derived 
tumors was buttressed by staining with a proliferation marker Ki67 antibody (B126.1, 
1:50, Abcam). No primary antibody was added in controls. 
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Supplementary Tables 
 
Supplementary Table I Primers used for RT-PCR 
 
 
 
Supplementary Table II  - Cell surface antigen expression in mesothelioma cell 
lines and primary cultures analyzed by flow cytometry 
Cell line CD105 Thy1 (CD90) CD73 PDPN ABCG2 
ZL55 +++ +++ +++ + + 
ZL55 SPT +++  +++ +  
ZL55 NSPT3-3 +++   +++  
SDM103T2 +++ +++ +++ +++ + 
SDM138 +++ +++    
ZL34 +++ +++ +++ +++ + 
H28     + 
 
(+) = 0 – 10% positivity; (++) = 11 – 50 % positivity; (+++) = 51 - 100% positivity 
 
 
  
gene name 
 
forward primer 
 
reverse primer 
 
mGli-1 
 
GCTGCAACCTTCTTGCTCACACAT GCTGCAACCTTCTTGCTCACACAT 
mPatch1 
 
TGGCCCATGCATTCAGTGAAACAG TAGGGATCAATGCGGCCATGAAGA 
mSca-1 TGGATTCTCAAACAAGGAAAGTAAAGA ACCCAGGATCTCCATACTTTCAATA 
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Supplementary Figures 
 
Supplementary Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
B 
A) The promyelocytic 
leukemia cell line 
HL60/Dox selected by 
chronic exposure to 
doxorubicin was used 
with both DyeCycleViolet 
(DCV) and Hoechst 
33342. Verapamil 
treatment resulted in a 
better separation of 
SP/NSP with DCV. 
 
 
 
 
 
 
 
 
 
 
 
B) MCF-7 cells were 
used as positive control 
for low level SP. 
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Supplementary Figure 2. 
 
 
 
 
 
 
 
 
 
 
Hoechst 33342 (0 to 50 g/ml) and DCV (0 to 100 M) (Sigma – Aldrich) or DCV 
(Invitrogen) were tested in DMEM/F12+GlutaMax (GIBCO) supplemented with 2% 
FCS and 10 mM HEPES (GIBCO), for 90 min at 37°C. Then drugs were removed 
and cells were grown for further 3 days at 37°C before performing an MTT assay to 
determine cytotoxicity. 
 
 
Supplementary Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) Representative gating strategy for single cell setting in cell surface phenotyping 
 
A 
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and B) exclusion of dead cells in SP cell sorting 
 
 
Supplementary Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
Colony forming efficiency was 
performed on freshly sorted 
SP and NSP cells by plating 
500 cells/well in 6-well plates. 
Colonies were stained with 
crystal violet after 10 days. All 
colonies with more than 30 
cells were counted. Freshly 
sorted SP and NSP from ZL55 
SPT yielded compact and 
loose colonies and colony 
forming efficiency (CFE) of 
loose colonies was 
significantly (p<0.01, n=6) 
higher in NSP fraction. A 
similar difference was 
observed for ZL34 cells. 
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Supplementary Figure 5. 
 
 
 
 
 
 
 
 
 
 
A) ZL55- and B) SDM103T2-derived tumors express N-cadherin, mesothelin and 
calretinin. 
 
 
Supplementary Figure 6. 
 
 
 
 
 
 
 
 
 
 
 
 
D2-40 immunostaining shifts from membrane to cytosol in recurrence tumors for 
SDM86 (A) and SDM102 (B). 
 
A B 
A B 
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Supplementary Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Upon exposure to asbestos fibres, undifferentiated mesenchymal mesothelium 
precursor cells or differentiated mesothelial cells undergo oncogenic events 
(reviewed in [51]) leading to loss of function of NF2 and INK4A tumor suppressor 
genes and tumor development. CD105-/low SP cells within these tumors are 
chemoresistant and have higher tumorigenic capacity leading to sarcomatoid 
evolution of the tumor. 
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6 DISCUSSION 
 
The aim of this PhD study was to identify and characterize cancer stem cells in ma-
lignant pleural mesothelioma. Since no stem cell marker has been yet identified for 
the mesothelium we used a functional assay. 
We observed that SP cells in MPM are accompanied by enrichment in ABCG2 and it 
can be inhibited by a specific ABCG2 inhibitor. Hence, a legitimate question would be 
whether it might be worth to sort ABCG2 positive cells, instead of using a functional 
assay. However, NSP cells do also express ABCG2 as observed at protein and 
mRNA level although at much lower levels. Therefore sorting ABCG2 positive and 
negative cells might be difficult to separate. In addition, Patrawala et al. observed that 
breast, glioma and prostate cancer SP cells were more tumorigenic compared to 
NSP cells, but ABCG2+ and ABCG2- cells, sorted by using the 5D3 antibody which is 
the only antibody available for sorting living cells, had the same tumorigenic potential 
in vivo (Patrawala et al., 2005). A characteristic of 5D3 antibody is that its binding is 
ABCG2 conformation dependent which may add difficulty in the interpretation of the 
results (Ozvegy-Laczka et al., 2005). This additional argument suggests that it is not 
wise to sort potential cancer stem cells according to ABCG2 surface expression, ra-
ther than using the dye efflux assay dependent on ABCG2 function. It is assumed 
that cancer/tissue stem cells need functional ABCG2 to keep their self-renewal po-
tential. This is supported by the observation of Susanto et al., where ABCG2 function 
was inhibited by its specific inhibitor FTC leading to decreased Nanog expression 
(embryonic stem cell marker) in embryonic mouse stem cells (Susanto et al., 2008). 
Furthermore, the FTC treated cells lost their self-renewal potential (Susanto et al., 
2008). In addition overexpression of ABCG2 in murine hematopoietic stem cells kept 
them in an undifferentiated state (Zhou et al., 2001). Taken together, these findings 
support the assumption that side populations, dependent on functional ABCG2, har-
bor cancer/tissue stem cells and functional ABCG2 is needed for their self-renewal 
potential. Therefore the side population assay is an appropriate method to isolate 
potential cancer stem cells. 
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According to the cancer stem cell model, CSCs should induce a phenocopy of the 
original tumor in vivo (Reya et al., 2001). The potential of cancer stem cells to induce 
tumor growth or their clonogenic potential tested by in vitro models like colony for-
mation assays or, where possible, by sphere formation assays represent good sup-
portive experiments and offers the opportunity to test the chemoresistance of cancer 
stem cells in vitro. Nevertheless, they do not take into account possible extracellular 
factors supporting cancer stem cell functions in vivo (Brennan and Matsui, 2009). The 
capacity of tumor growth in vivo is often tested in NOD/SCID mice (the gold standard, 
(Fillmore and Kuperwasser, 2007), (Jones, 2009)), sometimes irradiated before im-
plantation of selected cells to further suppress a mouse’s immune system. For that 
purpose Quintana et al. used NSG mice to investigate the tumorigenicity of potential 
melanoma stem cells (Quintana et al., 2008). NSG mice are NOD/SCID mice in 
which the interleukin-2 receptor is knocked down leading to a lack of natural killer 
(NK) cells. Thus, the NSG mice are highly immunocompromised. By comparing tu-
mor growth of transplanted human melanoma cells into NOD/SCID and NSG mice, 
they observed that tumors grew faster in NSG mice and increased tumor-initiating 
frequency were observed (Quintana et al., 2008). The in vivo system used by Quin-
tana et al. suggesting that in melanoma no cancer stem cells are present, was further 
investigated by Civenni et al. (Civenni et al., 2011). They sorted melanoma cells ac-
cording to their CD271 expression and injected them into NOD/SCID, NSG or 
NOD/SCID mice, in which NK cells were depleted. Comparing tumorigenicity of 
CD271+ and CD271- melanoma cells in the different mouse models and investigating 
the heterogeneity of newly developed tumors in these mice revealed that first of all 
CD271+ cells represent melanoma stem cells with self-renewal potency and multipo-
tent capacity. Contrary to tumors developed from CD271+ in NOD/SCID, NSG mice 
developed tumors different from the parental tumors suggesting a role for NK in al-
lowing phenocopying parental tumors as it would be expected from stem cells 
(Civenni et al., 2011). 
In the NOD/SCID mouse model used in this study, we observed in the first tumor 
generation no difference in tumorigenic potential between freshly sorted SP and NSP 
cells of a MPM cell line. Tumors developed from second round SP and NSP cells 
showed a tendency toward increased tumorigenicity of SP cells compared to NSP 
cells. This observed tendency is in line with the observation done by Roesch et al. 
(Roesch et al., 2010). They investigated JARID1B (H3K4 demethylase) expressing 
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melanoma cells with the potential to be cancer stem cells. Serial transplantation as-
says were used to investigate the long-term tumorigenic potential of JARID1B posi-
tive and negative cells during three passages and observed that JARID1B negative 
cells exhausted their tumor initiating capacity (Roesch et al., 2010). Also Civenni et 
al. observed long-term tumorigenic potential of CD271+ melanoma cells over five 
passages (Civenni et al., 2011). This suggests that NSP cells of MPM could lose their 
tumor growth potential after more than three passages in vivo, whereas SP cells 
should keep their tumor initiating potential in vivo, the tendency we already observed. 
For this purpose, more in vivo experiments would have been needed. 
However, injection into immunocompromised mice can also be questioned. An ideal 
solution to overcome this problem would be the usage of a syngeneic in vivo mouse 
model. In such a model, tumor cells and potential cancer stem cells of a mouse tumor 
can be injected into healthy syngeneic mice. Jongsma et al. developed a mouse 
model in which mice developed mesothelioma within some hundreds of days 
(Jongsma et al., 2008). They used the Cre-LoxP system to conditionally knock out 
Nf2, Trp53, Rb and/or Ink4a/Arf tumor suppressor genes (Jongsma et al., 2008). 
These genes have been found to mostly be inactivated/deleted in mesothelioma (see 
introduction 3.1.7). Differential tumor initiating properties of SP vs. NSP cells derived 
from tumors of these mice could be investigated to evaluate the role of the immune 
system during tumor development. 
 
Moreover, the SP fraction of MPM was enriched for tumor initiating cells and we have 
some evidences that in MPM this function is due to ABCG2. Therefore it might be 
appropriate to investigate therapies which abolish the function of ABCG2. To be ac-
tive ABCG2 has to be inserted into the cell membrane (Bleau et al., 2009), (Mogi et 
al., 2003) and this process is regulated by PI3K/Akt signaling. Mogi et al. showed that 
indeed PI3K/Akt modulates ABCG2 cell membrane insertion in murine bone marrow 
cells (Mogi et al., 2003). Further, the treatment of T-cell acute lymphoblastic leukemia 
using NVP-BEZ235, a PI3K/Akt/mTOR inhibitor which is already in clinical trials 
(Maira et al., 2008), synergized conventional chemotherapeutics (Chiarini et al., 
2010). In addition, they showed that NVP-BEZ235 targeted SP cells by decreasing its 
fraction and ABCG2 cell membrane expression/insertion. 
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Beside its ABCG2 membrane insertion, PI3K/Akt pathway may additionally be in-
volved in mesothelioma progression (Opitz et al., 2008). Indeed, the decrease of a 
well-known endogenous inhibitor of the PI3K/Akt pathway, phosphatase and tensin 
homologue (PTEN) was associated with a worst outcome for patients. 
 
In our study we additionally observed a “backward to precursor” transition as meso-
thelioma progresses from epithelioid via biphasic to sarcomatoid histotype in the 
three patients investigated. Due to this observation and the increased potential of SP 
cells to induce the growth of tumors containing spindelioid cells, we hypothesize that 
MPM SP cells are responsible for recurrence in patients. Since we analyzed relapse 
samples from only three patients, this observation will need to be corroborated in a 
bigger cohort of patients. 
The question remains if SP cells are transformed mesothelial stem cells or if they 
dedifferentiated from tumor cells which re-acquired stem-like properties as recently 
proposed (Gupta et al., 2009). 
It had been hypothesized that after injury mesothelium is repaired through recruit-
ment of submesothelial mesenchymal precursors or bone marrow-derived circulating 
precursors, possibly, mesenchymal stem cells (Mutsaers et al., 2007). In a sur-
faceome screen performed in our laboratory, the expression of two well established 
mesenchymal stem cell markers (MSC) (Dominici et al., 2006), CD90 (Thy1) and 
CD73, were observed to be expressed on mesothelioma cells (Ziegler et al., manu-
script submitted). The expression of CD90 on mesothelioma cells was confirmed in a 
recent publication (Melotti et al., 2010). These observations together with the possi-
ble role of MSC in mesothelium repair as we would expect after asbestos injury, lead 
us to investigate the expression of the third essential MSC marker CD105 (endoglin) 
(Dominici et al., 2006). We surprisingly observed that all MPM cells in vitro were posi-
tive for those markers. 
Since MSC markers on MPM cells were detected in vitro it would be interesting to 
investigate if and to what percentage these MSC markers are expressed in MPM in 
vivo. This has already been tested for CD90 immunoreactivity on frozen samples and 
only few mesothelioma cells were positive (Ziegler et al., manuscript submitted). This 
in vitro vs. in vivo discrepancy warrants further investigations. The other two markers 
still need to be investigated in vivo. If in vivo mesothelioma cells with expressing 
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MSC markers are indeed rare, it would be interesting to investigate whether sorted 
MSC marker positive MPM cells would have higher tumor initiating capacity in 
NOD/SCID mice. In addition, it would be interesting to investigate differentiation po-
tential of freshly isolated MSC marker positive MPM into osteoblast-, adipocyte- and 
chondrocyte-like cells. It would support the notion that multipotentiality is maintained 
in cancer and would provide potential perspective for therapeutic intervention. This 
would be especially important, if MSC positive cells would have higher tumor initiating 
capacity. 
As described in the results part, MPM SP cells were enriched for CD105-/low cells. 
CD105 was the only one of the three MSC markers which has a wide range of ex-
pression levels in MPM and CD105-/low cells were more tumorigenic which raises the 
question what function CD105 could have in mesothelioma development/biology. 
As mentioned in the manuscript (results part), CD105 is an accessory TGF- recep-
tor expressed mostly but not exclusively on vascular endothelial cells (reviewed by 
(Lopez-Novoa and Bernabeu, 2010)). Its expression is low in resting endothelial cells 
(reviewed by (Lopez-Novoa and Bernabeu, 2010)) but high in proliferating vascular 
endothelial cells (reviewed by (ten Dijke et al., 2008)). Further, CD105 has a pivotal 
role in vascularization and CD105-null mice die by the age of E10.5 (Arthur et al., 
2000). In human embryogenesis CD105 expression on mesoderm-derived vascular 
endothelium is observed during the development of the cardiovascular system start-
ing from week 4 onward (reviewed by (Lopez-Novoa and Bernabeu, 2010)). In a 
prostate carcinoma cell line CD105 down-regulation was observed together with ma-
lignant progression (Lopez-Novoa and Bernabeu, 2010) and CD105 overexpression 
in esophageal squamous cell carcinomas reduced its tumorigenicity (Lopez-Novoa 
and Bernabeu, 2010). Since CD105 is a receptor for TGF- a possible question is 
whether TGF- modulates MPM growth. TGF- has ambiguous functions: on one 
hand it has tumor suppressive and on the other hand pro-oncogenic activities (re-
viewed by (Roberts and Wakefield, 2003)). Its activity depends on the tumorigenic 
stage at which it plays a role. In the premalignant stage it has a tumor suppressor 
function (Roberts and Wakefield, 2003). This switches to pro-oncogenic at later stag-
es which lead to tumor invasion and metastasis (Roberts and Wakefield, 2003). 
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TGF- treatment of mesothelial cells in vitro induced EMT (Mutsaers and Wilkosz, 
2007). Overexpression of TGF- has been observed in MPM tumor cells often corre-
lated with a poor prognosis (summarized by (Suzuki et al., 2007)). 
If CD105-/low cells grow faster in vivo compared to CD105high cells it would be as-
sumed that TGF- has a negative regulatory role. However ATRA which has been 
used to efficiently arrest the growth of MPM in vivo was shown to decrease TGF- 
(Tabata et al., 2009) which may suggest that TGF- is a growth stimulant. 
 
An additional point which would deserve to be addressed is whether SP cells would 
be WT1 negative, since WT1 is a marker for fetal and adult human mesothelial tis-
sues (Amin et al., 1995) and sarcomatoid MPM loose WT1 expression. Assuming SP 
cells are WT1- and NSP cells WT1+, this would be indicative that indeed SP cells de-
differentiated from MPM WT1+ cells towards mesothelial precursor cells. On the other 
hand, assuming SP cells are WT1+, what would be the regulating mechanism de-
creasing WT1 expression of SP cells in vivo? It is known that WT1 expression is lost 
upon EMT (Bax et al., 2011), but the mechanism regulating WT1 expression is still 
unknown. Initially, WT1 was thought to function as tumor suppressor gene, but in re-
cent years evidences suggested an oncogenic function of WT1 in some cell lineages 
(reviewed by (Hohenstein and Hastie, 2006)). Indeed, in some cases such as Wilms’ 
tumor loosing WT1 has oncogenic effects (reviewed by (Hohenstein and Hastie, 
2006)). WT1 expressing adult tumors are assumed to be mostly of epithelial origin 
and progress via EMT to tumors with worst prognosis (reviewed by (Hohenstein and 
Hastie, 2006)). 
Going into a similar direction, it would be interesting to investigate the function of 
podoplanin during MPM progression, because podoplanin expression shifted from 
the cell membrane towards the cytoplasm as MPM progressed from epithelioid to 
sarcomatoid histotype (results part). This phenomenon has already been observed in 
clinical samples (Padgett et al., 2008) but it has not been further investigated and 
diagnostic pathologists score only membranous podoplanin at the moment. 
During embryogenesis podoplanin is expressed in different tissues which are well 
separated in time and space (Gittenberger-de Groot et al., 2007). They include the 
coelomic cavity epithelium (investigated by immunohistochemistry of mouse embryos 
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using antipodoplanin clone 8.1.1) (Gittenberger-de Groot et al., 2007), splanchnic 
mesoderm which is the embryonic origin of the pleura (Gittenberger-de Groot et al., 
2007), (Mahtab et al., 2008), osteoblasts (investigated by immunohistochemistry of 
rat tissues using antibody clone E11) (Wetterwald et al., 1996) which originates from 
MSC and in lymphatic endothelium where it is under the control of the lymphatic en-
dothelial cell determining Prox1 gene (summarized by (Schacht et al., 2003)). 
Podoplanin is a transmembrane protein with an extracellular, transmembrane and 
cytoplasmic domain. It was shown that its cytoplasmic domain is necessary to induce 
EMT via activation of RhoA, a member of the Rho GTPase family involved in cyto-
skeletal rearrangements (summarized by (Martin-Villar et al., 2006)). Further, it was 
shown, that podoplanin binds with its cytoplasmic domain to members of the ERM 
(ezrin, radixin, meosin) protein family, which links integral membrane proteins to the 
actin cytoskeleton (Martin-Villar et al., 2006). Additionally, they showed that neither 
deletion of the extracellular domain nor mutations of the cytoplasmic cytoskeleton 
binding domain or its deletion influenced podoplanin localization at the cell surface 
(Martin-Villar et al., 2006). On the other hand, Fernández-Muñoz et al. observed the 
requirement of the transmembrane and cytoplasmic domain of podoplanin to be lo-
calized at lipid rafts of the cell membrane (Fernandez-Munoz et al., 2011). The lack 
of its insertion into these membrane structures inhibited EMT (Fernandez-Munoz et 
al., 2011). It is generally assumed, that podoplanin plays a role in tumor cell invasion, 
migration and metastasis, which are hallmarks of malignant tumors (Wicki and 
Christofori, 2007). Furthermore, it has been suggested, that podoplanin induces tu-
mor invasion without E- to N-cadherin switch, an EMT characteristic (reviewed by 
(Wicki and Christofori, 2007)). 
In our study, MPM cells of spindeloid morphology had increased podoplanin expres-
sion compared to cells of epithelioid morphology. As Martin-Villar et al. suggested, 
podoplanin might be involved in tumor progression (summarized by (Martin-Villar et 
al., 2006)). Podoplanin expression in mesothelial precursor tissues supports the ne-
cessity to investigate the tumor progression capacity of podoplanin positive MPM 
cells. 
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7 CONCLUSION 
The data obtained in this study provide evidence for a role of SP cells in mesothelio-
ma progression and suggest that SP cells resemble mesothelial precursor cells. 
The identification of the mechanism regulating the function of ABCG2 responsible for 
the SP phenotype will allow targeted chemotherapy in combination with cispla-
tin/pemetrexed in order to not only erase cancer cells but also cells responsible for 
relapse and chemoresistance. 
The data presented in this study add knowledge about MPM biology and identify po-
tential new interesting markers of tumor progression. 
 
 
8 FUTURE PERSPECTIVE 
Our work may inspire the screening of a large cohort of patients for the histological 
evolution of epithelioid MPM to evaluate the validity of the model of epithelial to sar-
comatoid progression. We have provided some markers, membranous podoplanin 
and nuclear WT1 as tools for early EMT assessment. These markers are already 
used in pathology, so this would not be difficult to implement. This study would be 
feasible within a network of centers (e.g. the recently founded European Thoracic 
Oncology Plateform) collecting biopsies for diagnostic purposes and again at surgery. 
Although patients undergoing surgery represent only a minority of MPM patients, it 
should be possible to reach within such structure enough clinical samples to be in-
formative. If such a study would confirm the hypothesis it would add a significant ar-
gument in favour of EMT existence in tumor progression. This has been recently 
challenged in this year’s Association for Cancer Research (AACR) meeting, where 
the pathologist David Tarin questioned the EMT supposed to be responsible for inva-
sion and metastasizing simply because this process has never been observed in ac-
tion in human cancers (Ledford, 2011).  
 
In general, it is a big issue to improve malignant pleural mesothelioma treatment due 
to reasons mentioned in this study. Prevention represents a real advancement for the 
protection of the population against asbestos fibers and one step into this direction 
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was done, when the use of it was banned. Unfortunately, this is not true for all parts 
of the world. Especially in third world it still might be in use or its elimination and de-
posit occurred improperly. MPM incidence still rises in Europe where asbestos has 
been banned and in the developing countries not much is known, but it is likely that 
incidence is rising there as well and it will not decrease so soon ([Anon], 2010). The 
potential danger of MPM caused by carbon nanofibers which have the same physical 
properties as asbestos fibers is only now beginning to be evaluated (Donaldson et 
al., 2010), (Poland et al., 2008). Due to the difficulties in the diagnosis of MPM, early 
detection and preventing its malignant progression might represent a way to improve 
the outcome. In this respect MPM biology and its malignant progression needs to be 
better understood. 
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IMIG TNM staging system. Adapted from Moore, 2008. 
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